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Hot Flashes in Men with Prostate Cancer: Prevalence, Severity, and Psychosocial
Correlates
Erin Winters
ABSTRACT
The present study evaluated the prevalence, severity, and psychosocial correlates
of hot flashes in men receiving androgen deprivation therapy for prostate cancer.
Seventy-two men completed a detailed packet of questionnaires prior to the initiation of
treatment and again three-months later. Results indicated that the extent to which hot
flashes interfered with patients daily functioning significantly contributed to changes in
depressive symptoms. Changes in fatigue were found to mediate the relationship between
hot-flash related interference and depressive symptomatology, suggesting that increases
in fatigue were responsible for the concurrent increases in symptoms of depression. The
coping strategy of catastrophizing moderated the relationship between hot flash-related
interference and cancer-related distress, such that levels of cancer-related distress in men
reporting greater use of catastrophizing were dependent upon levels of hot flash-related
interference. Men who did not engage in catastrophizing reported uniformly low levels of
cancer-related distress regardless of the extent to which hot flashes interfered with daily
functioning. Expected relationships between hot flashes and sexual functioning or
masculine self-image were not confirmed. These findings provide valuable information
regarding the experience of hot flashes in this population. Results indicate that reduction
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of fatigue may lead to reductions in depressive symptoms, while reducing patients use of
catastrophizing may alleviate cancer-related distress.
1Although hot flashes are a commonly recognized side effect of hormonal therapy
for prostate cancer, limited research exists to describe the psychosocial impact of this
gender-inconsistent experience. Other side effects of prostate cancer treatment, such as
sexual, urinary, and bowel impairment have received greater attention in terms of their
impact on daily functioning and quality of life. The purpose of the current investigation is
to identify the psychosocial correlates of hot flashes in men with prostate cancer
undergoing hormonal therapy and to identify potential mediators and moderators of the
relationship between hot flashes and psychological distress. The introduction begins with
background information on the role of hormonal therapy in the treatment of prostate
cancer. This section includes information about the prevalence of hot flashes in men with
prostate cancer and a brief explanation of how hot flashes can be induced by hormonal
therapy. A review of the literature that has assessed the common side effects of hormonal
treatment follows. Much of this research has focused on the role of hormonal therapy in
producing decrements in sexual functioning and overall quality of life. Because relatively
little research has been conducted on hot flashes in men with prostate cancer, discussion
will then turn to research that has investigated the impact of hot flashes in women with
breast cancer. Correlates and predictors of hot flashes in this population will be
highlighted as they may apply to men with prostate cancer. The introduction concludes
with a discussion of variables that might serve as mediators and moderators of the
relationship between hot flashes and psychological distress.
2Hot flashes and hormonal therapy
Although hot flashes are typically regarded as a naturally occurring symptom of
female menopause, men treated with hormonal therapy for prostate cancer also
experience hot flashes. A significant number of men undergoing this form of treatment
have reported experiencing hot flashes, with estimates ranging from 57% (Potosky et. al.,
2001) to 74% (Spetz, Hammar, Lindberg, et. al., 2001). Because hot flashes and their
associated distress are prevalent in this patient population, it is important to understand
the phenomenon and the factors associated with it. A hot flash has been defined as, a
transient episode of flushing, sweating, and a sensation of heat, often accompanied by
palpitations and a feeling of anxiety, and sometimes followed by chills (Kronenberg,
1994, p. 320). This experience may vary from person to person in terms of frequency,
severity, and duration. Hot flashes are a consequence of reductions in estradiol, which
can result from natural menopause, removal of the ovaries or testes, or use of hormone
agonists or antagonists (Fitzpatrick & Santen, 2002). Lutenizing hormone-releasing
hormone (LHRH) agonists are the most frequently used of these agents and have
revolutionized the treatment of advanced prostate cancer. Use of these hormonal agents
causes a chain of events in the body that eventually leads to a decrease in testosterone
production (Hellerstedt & Pienta, 2002). This accomplishes the goal of slowing the
growth of the cancer, but also produces several unwanted effects, including hot flashes.
The purpose of hormonal therapy in men with prostate cancer is to decrease the
production of testosterone by the testes or to block the action of testosterone on the
prostate cells. This can be accomplished surgically, by removal of the testes
(orchiectomy) or medically, by injecting drugs that prevent production of testosterone by
3the testes. Hormonal therapy is not a cure for prostate cancer, but rather a means of
slowing its growth and reducing the size of the tumor. Hormonal therapy, or androgen
deprivation therapy as it is often referred to, is used to treat patients with varying stages
of disease. In the early stages of a prostate cancer diagnosis, hormonal therapy may be
prescribed in men with large prostate glands as a means of reducing the size of the
prostate in preparation for brachytherapy or radiation. At the later stages it can be used to
treat men considered to be biochemical failures, in that the first line treatment
(prostatectomy, radiation, or brachytherapy) did not completely eliminate the cancerous
cells (Dreicer, 2002). This is evidenced by a steady rise in patients PSA values, which is
considered to be indicative of progressive disease. Because of the minimal burden on the
patient, as compared to prostatectomy or radiation, this form of treatment is often
attractive to those patients and clinicians who would prefer to take a slightly more active
role than the passive option of watchful waiting.
Side effects and related psychosocial sequelae of hormonal therapy
Existing research with men receiving androgen deprivation therapy has focused
mainly on the prevalence of, and bother associated with, the side effects of this form of
treatment. Recognized side effects include loss of libido and erectile dysfunction, hot
flashes, gynecomastia, weight gain, osteoporosis, anemia, changes in mood and cognitive
function, fatigue, and diminished quality of life (Chen & Petrylak, 2004). The following
section will review the recent literature that examines the relationship between use of
androgen deprivation therapy and quality of life. Research focusing specifically on the
role of hot flashes in men is somewhat sparse. The few studies conducted have been
4largely descriptive in nature and have not attempted to systematically explore the
psychosocial correlates of hot flashes.
Spetz and colleagues (2001) compared survival and quality of life outcomes in
men with metastatic prostate cancer randomly assigned to receive injections of
polyestradiol phosphate (a semi-synthetic estrogen) or undergo complete androgen
ablation via bilateral orchiectomy or injection of LHRH agonists. This investigation is
notable for its focus on hot flashes and the use of randomization to treatment groups. At a
follow-up assessment (median time = two years) 74% of patients in the androgen ablation
group were experiencing hot flashes compared to 30% of patients in the polyestradiol
phosphate group. Men in the androgen ablation group also reported experiencing
significantly more distress as a result of the hot flashes. Within the two-year follow up
period, half the men receiving polyestradiol phosphate were no longer experiencing hot
flashes, yet all the men on androgen ablation were still experiencing hot flashes to some
degree. These findings indicate that hot flashes are not a transient side effect, as was once
believed.
The Prostate Cancer Outcomes Study (PCOS) is a large-scale survey of newly
diagnosed prostate cancer patients. Using a subset of these data, Potosky and colleagues
(2001) compared quality of life outcomes for men receiving primary androgen
deprivation via surgical castration (orchiectomy) versus chemical castration (LHRH
agonists). These men did not receive any other form of treatment within the first 12
months of their diagnosis. Data were collected at six and 12 months after treatment. The
rate of hot flashes did not differ significantly between the two treatment groups, with
57% of men treated with LHRH agonists and 68% of men treated with an orchiectomy
5reporting this side effect. Although there were no differences between the two groups in
self-reported sexual functioning, significant overall declines were observed in several
domains. Of the men who reported normal pretreatment sexual functioning, 69% were
impotent after treatment. Additionally, 51% of the men with some interest in sex prior to
treatment reported a complete lack of interest afterwards and 73% ceased to engage in
sexual activity completely.
An overall weakness of the PCOS is the use of retrospective reports of baseline
(i.e., pretreatment) functioning. Participants were contacted six months after diagnosis, at
which time they were instructed to recall their health status as it was prior to treatment.
Although steps were taken to examine recall accuracy (Legler, Potosky, Gilliland, Eley,
& Stanford, 2000), the potential for recall bias cannot be eliminated completely.
Additionally, the study had an overall response rate of 62%, with non-responders being
more likely to be nonwhite and of lower socioeconomic status than responders (Potosky
et al, 1999). Therefore, generalization to nonwhite and lower socioeconomic status
patients must be made with caution. Finally, it is unclear whether patients chose these
therapies because of personal preferences or were advised to do so under the guidance of
their oncologists. Without random assignment, the potential confounding influence of
variables other than treatment on the experience side effects cannot be ruled out.
Another analysis based on data from the PCOS compared men receiving androgen
deprivation therapy as their primary form of treatment with men receiving no treatment,
otherwise known as watchful waiting (Potosky et. al., 2002). Findings indicated that
among men who reported normal sexual functioning at baseline, men who had received
androgen deprivation therapy reported less interest in sex, more breast swelling, and a
6greater number of hot flashes one year after treatment compared to those followed by
watchful waiting. Men receiving androgen deprivation therapy also reported higher
levels of physical discomfort due to prostate cancer, as well as more physical limitations
and greater bother attributed to the disease. As with the previous study, methodological
limitations included retrospective recall of baseline functioning, differential response
rates for age and SES, and non-random assignment to treatment groups. Another
confounding variable was cancer severity. It should be noted that receipt of androgen
deprivation therapy was associated with several indicators of more advanced disease,
including higher Gleason scores, higher PSA values, and a higher level of staging. The
greater discomfort and poorer physical functioning reported by androgen-deprived men
may have been partially due to the prostate cancer itself rather than the treatment received
by these men.
Other research in this area has yielded similar findings regarding the adverse side
effects of androgen deprivation therapy. Herr and OSullivan (2000) surveyed a group of
men with rising PSAs after local therapy. This sample was obtained by recruiting from
attendees at a prostate cancer support group. These men had been offered the choice of
immediate androgen deprivation therapy (either orchiectomy or administration of LHRH
agonists) or observation with deferred androgen deprivation therapy. Men who had
chosen to receive immediate androgen deprivation therapy reported greater fatigue, worse
physical functioning, greater psychological distress, greater sexual problems, and lower
overall quality of life than men who chose observation. Further comparisons revealed that
men who opted for androgen deprivation therapy using LHRH agonists reported a greater
number of problems than did the men who had an orchiectomy. Specifically, they
7reported a lower overall quality of life, greater psychological distress, a greater number of
cancer-related intrusive thoughts, and greater fatigue. Hot flashes were not assessed.
When considering the results of this study it is important to keep in mind that the sample
used was self-selected. Participants were recruited from a prostate cancer educational
support group conducted by the authors. The ways in which these men may differ from
prostate cancer patients not attending a support group is unknown. Additionally, these
men were not randomly assigned to receive androgen deprivation therapy, but were able
to choose which treatment to receive. The possibility exists that some of the observed
differences may reflect characteristics of the men themselves rather than the impact of the
treatment they chose.
Androgen deprivation therapy is also used to treat prostate cancer patients with
metastatic disease. Despite the fact that the disease is more widespread, these men report
similar problems. Herr, Kornblith, and Ofman (1993) assessed patients with metastatic
disease who chose to receive or defer hormonal therapy. Patients who chose hormonal
therapy reported less sexual interest and enjoyment, increased fatigue, and a greater
number of physical symptoms at a six-month follow-up assessment. Although the battery
of questionnaires used included an item assessing hot flashes, the results for this item
were not reported. Because of the nonrandom nature of the study, these results must be
interpreted with caution.
Fowler and colleagues (2002) compared quality of life in men treated with
androgen deprivation after prostatectomy and men treated with prostatectomy alone.
Treatment side effects examined included urinary incontinence, erectile dysfunction, and
loss of libido. Men treated with androgen deprivation reported less ability to have sexual
8intercourse and fewer days of feeling sexual drive than men treated with prostatectomy
alone. Analyses regarding quality of life were performed both with and without men with
metastatic disease in order to examine the role of the recurrence itself. Results of both
analyses were similar. Men who had received androgen deprivation therapy reported that
cancer and its treatment had a bigger negative effect on their lives, reported more
concerns about body image, and reported more worries about death and dying than men
who did not receive androgen deprivation therapy. Additionally, they reported worse
scores on indices of mental health, general health, and activity. Weaknesses of this study
included the use of questionnaires that had not been previously validated, a cross-
sectional design, and non-random assignment to treatment groups.
Other research suggests that compared to other forms of treatment, androgen
deprivation therapy may be associated with more longstanding declines in health-related
quality of life. Lubeck, Grossfeld, and Carroll (2001) evaluated several aspects of quality
of life in men treated with prostatectomy, radiation, androgen deprivation therapy, or
surveillance as part of the Cancer of the Prostate Strategic Urologic Endeavor
(CaPSURE). Similar to the PCOS, CaPSURE is a national longitudinal study of men with
prostate cancer. The timing of the first assessment varied based upon the time of
enrollment in the study. For some men this was prior to the initiation of any type of
therapy, for others it was some time afterwards. Sexual, urinary, and bowel function
were assessed, but evaluation of hot flashes was not within the scope of this study. Of the
many areas of heath-related quality of life assessed, men on androgen deprivation therapy
experienced significant declines in sexual function and sexual bother only. As compared
to men in the other three treatment group, men receiving androgen deprivation therapy
9group had the highest percentage of patients with advanced disease. The researchers also
analyzed a subset of the data from men who had completed the questionnaires before and
after initiation of androgen deprivation therapy. Significant decrements were found in
sexual functioning six months after treatment began. Strengths of this investigation
included the use of well-established tools to assess both general and health-related quality
of life. The lack of randomization to treatment conditions prohibits firm conclusions
regarding the changes in quality of life due solely to treatment.
In an attempt to provide information regarding the prevalence, severity, and
correlates of fatigue in men receiving hormonal therapy, Stone and colleagues (2000)
assessed 62 men with prostate cancer prior to and three months after initial receipt of an
LHRH analogue. At the three-month assessment, 66% of patients reported an increase in
fatigue, with 42% of men reporting an increase of 10 points or more (on a scale ranging
from 9-63). Seventeen percent of men met the criteria corresponding to severe fatigue.
Although there was a strong relationship between fatigue and psychological distress at
the baseline assessment, the increase in fatigue was not associated with a concurrent
increase in distress. Pre-treatment measures of fatigue accounted for 32% of the variance
in fatigue score at the three-month follow-up. None of the other variables assessed
(quality of life, functional abilities, psychological distress, nutritional status, other
symptom severity) were significant predictors of fatigue levels three months after the
initial injection.
In an investigation focusing on rates of depression in men receiving androgen
deprivation therapy, Pirl and colleagues (2002) reported a prevalence rate of 12.8% as
assessed by the Structured Clinical Interview for the DSM-IV (SCID). Similarly, 13.3%
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of patients reported symptoms consistent with a mild to moderate level of depression on
the Beck Depression Inventory (BDI). In this sample, rates did not differ by disease
stage, method of androgen deprivation (orchiectomy vs. GnRH agonist), androgen
dependence, or whether or not the patient was also receiving chemotherapy. Not
surprisingly, a prior history of depression was associated with reports of current
depressive symptomology. Because history of depressive symptoms was assessed
retrospectively, fluctuations in level of distress due to changes in hormonal states could
not be determined. Greater levels of depressive symptoms were correlated with increased
fatigue and lower levels of functioning. Although this study had a small sample size (N =
45), it highlights the need for appropriate attention devoted to assessment and diagnosis
of depression in this patient population.
In a sample of Japanese patients treated with androgen deprivation therapy,
approximately 58% reported experiencing hot flashes, of which 38% chose to pursue
treatment for this troubling side effect (Nishiyama, et. al., 2004). Patients with and
without hot flashes differed in terms of physical well-being, social/family well-being,
health-related quality of life, and overall quality of life. Men with hot flashes reported
more problems in each of these areas. This study suffered from several methodological
limitations, including a small sample size (N=55), cross-sectional data, and a
heterogeneous sample; however, it was the only study found that attempted to evaluate
changes in quality of life due to hot flashes.
The findings reviewed above outline many of the decrements in quality of life that
are associated with hormonal therapy for prostate cancer. Men receiving this form of
treatment often report declines in sexual functioning and interest, increased fatigue, hot
11
flashes, and declines in overall perceived physical health. They also report a significant
amount of psychological distress and declines in several aspects of quality of life.
Compared to men treated with prostatectomy, men treated with hormonal therapy report
greater concerns over body image, worry about death and dying, and distress due to
prostate cancer. Although hot flashes are a recognized side effect of this form of
treatment, relatively little attention has been paid to their psychosocial impact.
Psychosocial factors associated with hot flashes in women with breast cancer
Within the field of oncology, much of the research on hot flashes and their impact
on quality of life has been conducted in women with breast cancer. In addition to
naturally occurring menopause, women with breast cancer may be susceptible to hot
flashes due to surgically-induced menopause via removal of the ovaries (oophorectomy)
or chemotherapy-induced menopause. Some of the research on hot flashes in women with
breast cancer will be discussed as it may also pertain to men with prostate cancer.
Based on structured telephone interviews conducted with postmenopausal women
with breast cancer, Carpenter and colleagues (1998) found that 65% reported hot flashes.
More severe hot flashes were associated with a higher body mass index (BMI), younger
age, and use of tamoxifen (an anti-estrogenic agent). Comparisons were also made
between women with and without hot flashes on quality of life variables. Although none
of the comparisons reached the criterion set for statistical significance, there was a trend
for women with hot flashes to report poorer mental and physical quality of life. A similar
trend was found for differences between women with no hot flashes or mild hot flashes
and those with severe hot flashes. With the exception of tamoxifen use, the psychosocial
correlates listed above may also be applicable to men with prostate cancer.
12
Stein and colleagues (2000) explored the medical, psychosocial, and demographic
correlates of hot flashes in a sample of women currently undergoing breast cancer
treatment. In terms of psychosocial variables, women experiencing hot flashes reported
higher levels of fatigue, greater interference of fatigue with quality of life, poorer sleep
quality, and poorer physical health. More severe hot flashes were associated with greater
fatigue, poorer physical health, a greater impact of fatigue on quality of life, and higher
levels of global and somatic symptoms of fatigue. In order to determine the contribution
of hot flash prevalence to the variability in psychosocial and quality of life outcomes,
multiple regression analyses were conducted. After accounting for relevant medical,
demographic, and treatment variables, hot flashes accounted for an additional 11% of the
variance in physical health, an additional 15% of the variance in sleep quality, and an
additional 9% of the variance in fatigue. These findings suggest that hot flashes play a
significant role in regards to the development and impact of fatigue.
Carpenter, Johnson, Wagner, and Andrykowski (2002) took this line of research a
step further with the addition of an age-matched comparison group of healthy women.
Women with breast cancer were significantly more likely to be experiencing hot flashes
than women without breast cancer. Women with breast cancer also reported significantly
greater hot flash severity and bother compared to the healthy women. Among breast
cancer survivors, greater severity of hot flashes was associated with higher levels of
mood disturbance, negative affect, and interference of hot flashes with quality of life.
Hot flashes have also been assessed using objective assessment methods. In a
small pilot study, Carpenter and colleagues (2004) assessed 15 breast cancer survivors
and 15 healthy women matched on age, race, and menopausal status. Hot flashes were
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measured using sternal skin conductance monitoring during two 24-hour periods one
week apart. There was a trend towards a greater number of daytime hot flashes for breast
cancer survivors as compared to their healthy counterparts, but this difference did not
reach the criterion set for significance. When measured objectively, frequency of hot
flashes failed to correlate with sleep duration and global sleep quality. Although this
investigation suffered from a small sample size, it highlights the discrepant results
obtained using objective measurement of hot flashes.
Although information gathered from research conducted with women with breast
cancer may not directly relate to men with prostate cancer, it suggests several domains
that may be affected by hot flashes. Psychosocial variables associated with the hot flash
experience include higher levels of fatigue, higher levels of fatigue interference with
quality of life, poorer sleep quality, higher levels of mood disturbance, greater negative
affect, poorer mental and physical quality of life, and greater interference of hot flashes
with quality of life.
Potential mediators and moderators of the relationship between hot flashes and
emotional distress
The literature reviewed suggests that the experience of hot flashes in both men
and women is associated with some degree of psychological distress (Carpenter, et. al.,
1998; Carpenter, et. al., 2002; Fowler, et. al., 2002; Herr & OSullivan, 2000; Pirl, et. al.,
2002; Spetz, et. al., 2001). The current study will test the hypothesis that a similar
relationship between hot flashes and psychological distress is present in men with
prostate cancer receiving androgen deprivation therapy. Since the experience of hot
flashes is also associated with other adverse symptoms and states, it should be possible to
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explore whether the experience of these adverse symptoms and states mediate the
relationship between hot flashes and psychological distress. Sleep disturbance, fatigue,
and sexual dysfunction in particular, would appear to merit study as potential mediators
for two reasons. First, there is evidence to suggest that the experience of hot flashes is
associated with sleep problems and fatigue (Stein et. al., 2000), as well as sexual
dysfunction (Carpenter et. al., 2002). Second, there is evidence to suggest that the
experience of sleep problems, fatigue (Broeckel et. al., 1998; Stone et. al., 2000), and
sexual problems (Potosky et. al., 2001), are associated with psychological distress.
In addition to examining potential mediators of the relationship between hot
flashes and psychological distress, the present study will also examine potential
moderators of the relationship between hot flashes and distress. That is, the current study
will seek to identify variables that may interact with the experience of hot flashes to
produce greater psychological distress. Of particular interest are masculine self-image
and the coping process of catastrophizing.
Because hot flashes are typically a female experience, men with a strong
masculine self-image may be more distressed by the experience than those who are less
stereotypical in the way they define themselves. This idea is partially supported by
research suggesting that strong adherence to the dominant form of masculinity in the
United States may pose serious health risks for men (Sabo, 2000; Sabo & Gordon, 1995).
In contrast to other side effects of prostate cancer treatment, such as impotence or
incontinence, hot flashes are not an experience had by other aging men and are likely to
be considered as something only women experience. Therefore, men with strong
masculine self-concepts may be particularly distressed by hot flashes. Although there has
15
been a limited amount of research regarding the role of masculinity in coping with
prostate cancer, some studies have explored this construct.
Galbraith, Ramirez, and Pedro (2001) compared health-related quality of life,
health status, and masculinity in men undergoing various forms of treatment for prostate
cancer. These men were in one of four treatment groups: watchful waiting, conventional
radiation, proton-beam radiation, and a combination of conventional and proton-beam
radiation. Masculinity was assessed using the Bem Sex Role Inventory. Participants rated
how true each characteristic was of them, and also rated how important each
characteristic was to them, in order to assess the importance of sex-role identity. Over the
18-month study period, no differences in masculinity were found among the four groups.
Masculinity was significantly positively associated with general health and sexual
symptoms at the baseline assessment; however, there was no relationship between
masculine identity and health-related quality of life. This study did not include men
treated with hormonal agents; consequently the association between hot flashes and
masculinity was not explored.
Using freelists, single pilesorts, and other idiographic data collection techniques,
Stansbury, Mathewson-Chapman, and Grant (2003) evaluated veterans schemas
regarding masculinity and the relative importance given to gender attributes. Participants
were men with prostate cancer and a comparison sample made up of other hospital
patients (without prostate cancer), employees, and volunteers. Relative to the comparison
group, men with prostate cancer showed a tendency toward reduced emphasis on
domestic power, sexuality, and physical aspects of masculinity. The authors hypothesize
that this trend may reflect a reformulation of their concept of masculinity by reducing the
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importance of characteristics that may no longer apply to them. They acknowledge,
however, that to confirm this statement, these analyses must be conducted longitudinally
(i.e., while patients are going through treatment), in order to document a shift in
conceptualization. The authors also propose that men who fail to revise their masculine
concept will have a more difficult time adapting to the consequences of prostate cancer
treatment. They suggest that men who retain their image of masculine physicality are at
the highest risk for stress, depression, and interpersonal difficulties. Although this study
provided more theoretical insight than empirically supported conclusions, it affirms the
notion that a mans conceptualization of masculinity may affect his reaction to the
consequences of prostate cancer treatment.
The second proposed moderator of the relationship between hot flashes and
distress is catastrophizing. In times of stress, people who catastrophize often assume that
the worst will happen and feel helpless and unable to stop thinking about the stressful
experience (Sullivan, Bishop, & Pivik, 1995). It is hypothesized that men who experience
more severe hot flashes and also score highly on a measure of catastrophizing potential
will report higher levels of distress. Although catastrophizing has been linked to a variety
of deleterious health outcomes, it has never been examined in relation to the frequency or
severity of hot flashes. Reviewed below are several key findings in the oncology
literature regarding catastrophizing and other adverse symptoms.
Five studies can be identified that have examined the relationship between
catastrophizing and pain ratings in cancer patients. Of these five studies, three assessed
women with breast cancer (Bishop & Warr, 2003; Gaston-Johansson et. al., 1999;
Jacobsen & Butler, 1996), one assessed cancer patients with chronic pain (Lin, 1998),
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and the fifth assessed lung cancer patients (Wilkie & Keefe, 1991). Three of these studies
found evidence in support of a relationship between greater use of catastrophizing and
worse pain (Jacobsen & Butler, 1996; Lin, 1998; Wilkie & Keefe, 1991). Each study
utilized different methods of evaluating pain and catastrophizing. Although this evidence
is far from definitive, it provides some support for a relationship between catastrophizing
and cancer-related pain.
Catastrophizing has also been found to be associated with fatigue in cancer patient
populations. Broeckel, Jacobsen, Horton, Balducci, and Lyman (1998) investigated the
role of psychosocial variables in predicting fatigue severity in a sample of women who
had completed chemotherapy for breast cancer. Along with menopausal symptom
severity and sleep quality, the tendency to engage in catastrophizing was a significant
correlate of fatigue severity. In multiple regression analyses, catastrophizing accounted
for 14% of the variance in fatigue severity after accounting for menopausal symptom
severity.
Taking this line of work a step further, Jacobsen, Azzarello and Hann (1999)
explored the associations between catastrophizing and fatigue, quality of life, and
emotional distress in breast cancer patients. In this sample, a higher level of
catastrophizing was associated with more severe fatigue, greater depressive symptoms,
higher levels of state anxiety, and poorer quality of life. Catastrophizing was also found
to account for unique variance in depression, anxiety, and mental health after accounting
for levels of fatigue intensity.
There is also evidence to suggest that the impact of catastrophizing on fatigue
severity may be specific to the type of treatment received. Jacobsen, Andrykowski, and
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Thors (2004) found a significant treatment by catastrophizing interaction in a sample of
80 breast cancer patients. In this study, level of catastrophizing predicted subsequent
levels of fatigue severity and disruptiveness among women who had received radiation
therapy, but not for women who had undergone chemotherapy. These results indicate that
catastrophizing contributed more to fatigue severity among patients who received the less
inherently fatiguing of the two forms of treatment. Based on this pattern of results, it was
concluded that for the chemotherapy patients, the intensely fatiguing nature of the
treatment superseded the impact of any psychological variables.
Taken together, the findings in the oncology literature suggest that individuals
who catastrophize about the symptoms of their illness or side effects of treatment report
higher levels of those symptoms and side effects, and may also experience more distress
as a result. Although the findings presented above are specific to pain and fatigue, the
relationships found may be equally applicable to hot flashes.
As reviewed above, hot flashes are a prominent side effect of hormonal treatment
for prostate cancer. Unlike other side effects of this type of treatment, hot flashes in men
have received relatively little attention in the psychosocial literature. Because hot flashes
are a relatively unusual experience for men, it is important to understand the potential
psychosocial sequelae. The current study hopes to draw attention to this phenomenon by
providing information regarding the prevalence and severity of hot flashes in men
receiving hormonal therapy. In order to understand how hot flashes may result in
psychological distress, potential mediating and moderating relationships will be explored.
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Rationale and Aims
The aim of the current investigation is to examine the frequency, severity, and
psychosocial correlates of hot flashes in men treated with hormonal therapy for prostate
cancer. Toward this end, hot flashes and relevant psychosocial variables (described
below) were assessed in a group of men treated with hormonal therapy for prostate
cancer. These variables were assessed prior to the initiation of hormonal treatment and
again three months later. Hot flash prevalence, severity, and interference were also
assessed six weeks after the baseline assessment. In addition to characterizing the
frequency and severity of hot flashes over a three-month period following initiation of
hormonal therapy, the current study addressed the following hypotheses:
Hypothesis Set 1: Relationship of hot flashes to depressive symptomatology and cancer-
related, distress
1A. A worse experience of hot flashes (frequency, severity, score, and/or hot flash-related
interference) over the three-month period will be associated with a greater increase in
cancer-related distress as measured by the Impact of Events Scale (IES).
1B. A worse experience of hot flashes over the three-month period will be associated
with a greater increase in depressive symptomatology as measured by the Center for
Epidemiological Studies  Depression Scale (CES-D).
Hypothesis Set 2: Relationship of hot flash experience to sexual dysfunction, fatigue, and
sleep disturbance
2A. A worse experience of hot flashes over the three-month period will be associated
with a greater increase in fatigue as measured by the Fatigue Symptom Inventory (FSI).
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2B. A worse experience of hot flashes over the three-month period will be associated
with a greater increase in sleep disturbance as measured by the Pittsburgh Sleep Quality
Index (PSQI).
2C. A worse experience of hot flashes over the three-month period will be associated
with a greater increase in sexual dysfunction as measured by the sexual domain summary
score from the Expanded Prostate Cancer Index Composite (EPIC).
Hypothesis Set 3: Relationship of sexual dysfunction, sleep disturbance, and fatigue to
depressive symptomatology and cancer-related distress
3A. Greater increases in fatigue over the three-month period will be associated with
greater increases in cancer-related distress.
3B. Greater increases in fatigue over the three-month period will be associated with
greater increases in depressive symptomatology.
3C. Greater increases in sexual problems over the three-month period will be associated
with greater increases in cancer-related distress.
3D. Greater increases in sexual problems over the three-month period will be associated
with greater increases in depressive symptomatology.
3E. Greater increases in sleep disturbance over the three-month period will be associated
with greater increases in cancer-related distress.
3F. Greater increases in sleep disturbance over the three-month period will be associated
with greater increases in depressive symptomatology.
Based on the outcome of the first sets of hypotheses, we explored whether sexual
dysfunction, sleep disturbance, and/or fatigue mediated the expected relationship between
hot flashes and cancer-related distress and depressive symptomatology.
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Hypothesis Set 4: Moderating effects of masculine self-image in the relationship between
hot flashes and depressive symptomatology and cancer-related distress
4A. Masculine self-image (pre-treatment) as measured by the Bem Sex Role Inventory 
Short Form (BSRISF) will moderate the relationship between hot flash experience and
cancer-related distress.
4B. Masculine self-image (pre-treatment) will moderate the relationship between hot
flash experience and depressive symptomatology.
For each of these hypotheses it was anticipated that the combination of higher levels of
masculine self-image and a worse experience of hot flashes would be associated with
higher levels of cancer-related distress and depression.
Hypothesis Set 5: Moderating effects of catastrophizing in the relationship between hot
flashes and depressive symptomatology and cancer-related distress
5A. Catastrophizing potential (pre-treatment) as measured by the Hot Flash
Catastrophizing Scale (HFCS) will moderate the relationship between hot flash
experience and cancer-related distress.
5B. Catastrophizing potential (pre-treatment) will moderate the relationship between hot
flash experience and depressive symptomatology.
For each of these hypotheses it was anticipated that the combination of higher levels of
catastrophizing and worse hot flashes would be associated with higher levels of cancer-
related distress and depression.
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Method
Participants
Participants were men treated at the H. Lee Moffitt Cancer Center (HLMCC)
and James A. Haley Veterans Hospital (JAHVAH). To be eligible for participation,
these patients must 1) have been diagnosed with prostate cancer; 2) have been scheduled
to receive hormonal therapy (partial or complete androgen blockade) for a period of three
months; 3) have no clinical evidence of metastatic disease or have asymptomatic newly
diagnosed metastatic disease; 4) have no prior experience with hormonal therapy; 6) be
greater than 18 years of age; 7) be able to speak and read English; 8) have at least a sixth
grade education; and 9) be able to give informed consent.
Procedure
Eligible patients were identified with the assistance of oncologists treating these
patients and computerized medical records. Patients were approached during a clinic visit
prior to the initiation of hormonal treatment. Men who agreed to participate were asked to
sign an informed consent form (see Appendix A) and were given a packet of
questionnaires assessing demographic characteristics, fatigue, hot flashes, depressive
symptomatology, and other psychosocial variables. These questionnaires were completed
within one week of the patients first hormonal treatment and served as a baseline
measure for the variables of interest. Approximately six weeks after this initial
assessment, participants were telephoned at home. At this point, they were asked to report
on the frequency and severity of hot flashes within the previous two weeks, as well as the
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degree to which the hot flashes had interfered with several life domains. Participants
were asked to complete another packet of questionnaires approximately three months
after the initial baseline visit. For participants with a scheduled appointment at this time,
these assessments were completed in clinic. For those who were not scheduled to come to
HLMCC or JAHVAH, this was completed either by mail or telephone.
Measures
Demographic data. Demographic information was obtained through a self-report
questionnaire. Variables assessed include age, height, weight, race/ethnicity, marital
status, employment status, annual household income, and educational level. This
information was collected at the baseline assessment (see Appendix E).
Disease and treatment variables. The HLMCC computerized patient database
and medical charts were reviewed to obtain information on date of cancer diagnosis,
disease stage, recent PSA values, and other relevant disease and treatment characteristics.
Participants were also asked to provide a self-rating of their performance status
(Wingard, Curbow, Baker, & Piantadosi, 1991; see Appendix E).
Hot flashes. Hot flash frequency and severity were assessed using methods
similar to those used by Carpenter and colleagues (1998) in their evaluation of hot flashes
in postmenopausal women treated for breast cancer. Specifically, participants were asked
if they had experienced hot flashes in the previous two weeks. If the participant
responded affirmatively, he was be asked to estimate the number of hot flashes
experienced over the past two weeks and to rate their severity using a four-point scale (1
= mild; 4 = very severe). This information was collected at the first assessment and at the
six-week and three-month follow-up assessments. As in prior research (Sloan et. al.,
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2001), a total hot flash score was calculated by multiplying hot flash frequency by hot
flash severity. This method is preferred because it takes into account both frequency and
severity, providing an outcome measure that is sensitive to changes in either variable (see
Appendix F). Data collected at the first assessment were used to confirm that men were
not experiencing hot flashes prior to initiation of hormonal therapy. Men reporting hot
flashes at the baseline assessment were eliminated from analyses in order to provide a
homogenous sample in terms of experience with the variable of interest.
Hot flash interference. The Hot Flash Related Daily Interference Scale (HFRDIS;
Carpenter, 2001; see Appendix G) is a ten-item scale that assesses the level at which hot
flashes interfere with a variety of daily activities and overall quality of life. Interference
is rated on an 11-point scale (0 = do not interfere; 10 = completely interfere). Reliability,
convergent validity, construct validity, and sensitivity to change over time have been
shown in both breast cancer survivors and healthy comparison women (Carpenter, 2001).
This measure was included at all three data collection points (baseline, six-week follow-
up, three-month follow-up). In the present study, hot flash-related interference was
evaluated as a predictor of changes in sleep, mood, and sexuality. Items assessing the
degree to which hot flashes interfere with each of these three constructs are also included
in the standard version of the HFRDIS. To eliminate the potential confounding influence
of this construct overlap, these three items were eliminated from the version of the
HFRDIS used in the present study. The internal consistency reliability estimate for the
seven-item version of this measure was comparable to that of the original 10-item
measure (alpha = .98).
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Fatigue. The Fatigue Symptom Inventory (FSI; Hann et al, 1998; see Appendix
H) is a 14-tem scale that assesses the frequency, severity, and disruptiveness of fatigue.
Frequency is measured in two ways: the number of days fatigue was experienced in the
past week and the portion of the day on average the respondents felt fatigued. Most, least,
and average fatigue severity in the past week are measured on 11-point scales (0 = not at
all fatigued; 10 = as fatigued as I could be). Disruptiveness with quality of life in seven
different domains is also evaluated. These domains are assessed on separate 11-point
scales (0 = no interference; 10 = extreme interference). Responses to these seven items
are summed to provide a total interference score. Previous research has demonstrated the
reliability and validity of the FSI with individuals diagnosed with cancer (Hann et al.,
1998; Jacobsen et. al., 1999). For the purposes of the current study, the highest level of
fatigue in the past week was used as the outcome of interest. Fatigue was assessed at
baseline and three-month follow-up assessments.
Sleep quality. The Pittsburgh Sleep Quality Index (PSQI; Bussye et. al., 1988; see
Appendix I) is a 19-item scale designed to assess sleep patterns, quality, and disturbances
in the past month. For the purposes of the current study, a subset of seven items was used
and the timeframe of interest was reduced to the past week in order to be consistent with
the other measures given. The measure can be used to describe seven components:
subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep
disturbances, use of sleep medication, and daytime dysfunction. The PSQI has shown
acceptable reliability and validity when administered to both healthy and chronically ill
individuals. It has also been used in studies evaluating the impact of hot flashes in women
with breast cancer (Stein et. al., 2000; Weitzner et. al., 2002). For the current study, the
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primary outcome of interest was the item that assessed sleep quality. This was assessed
using a four-point scale (0 = very good; 3 = very bad). Habitual sleep efficiency was also
calculated and used as an additional outcome measure in exploratory analyses. These
indices of sleep were assessed at the baseline and three-month follow-up assessments.
Depressive symptomatology. The Center for Epidemiological Studies 
Depression Scale (CES-D; Radloff, 1977; see Appendix J) is a 20-item measure of
depressive symptomatology. Respondents rate how frequently they have experienced
each depressive symptom in the past week on a 4-point scale (0 = rarely or none of the
time; 3 = most or all of the time). Items are summed to produce scores ranging from zero
to 60. The CES-D has good internal consistency with alphas of .85 for the general
population and .90 for a psychiatric population (Radloff, 1977). The validity of the CES-
D has been demonstrated with a wide range of populations, including cancer patients
(Beeber, Shea, & McCorkle, 1998; Hann, Winter, & Jacobsen, 1999). Depressive
symptomatology was assessed at the baseline (alpha = .86) and three-month follow-up
(alpha = .91) assessments with good reliability estimates at each time point.
Cancer-related distress. The Impact of Events Scale (IES; Horowitz, Wilner,
Alvarez, 1979; see Appendix K) consists of 18 items designed to measure subjective
distress related to a particular event. For the purposes of the current investigation,
participants were asked to respond to each item in regards to their cancer and its
treatment. Item content reflects both intrusive thoughts and avoidant responses. These
subscales can be evaluated independently or a total distress score can be calculated by
summing all 18 responses. Total distress score was used in the current investigation.
Respondents were asked to indicate how frequently each comment was true for them
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during the past week using a four-point scale (0 =not at all; 1=rarely; 3=sometimes; 5 =
often). Previous research has supported the use of the IES as a measure of cancer-related
distress in a sample of breast cancer patients (Thewes, Meiser, & Hickie, 2001). Both
internal consistency (alpha = .91 for total scale) and test-retest reliability (r = .80 for total
scale) were acceptable in their sample. Cancer-related distress was assessed at the
baseline (alpha = .87) and three-month follow-up (alpha = .92) assessments with good
internal consistency estimates at each time point.
Masculine self-image. The Bem Sex-Role Inventory  Short Form (BSRISF;
Bem, 1981; see Appendix L) is a 30-item adaptation of Bem's original inventory
designed to investigate masculinity and femininity as independent dimensions of sex role
identity. Respondents are asked to rate themselves as to how well stereotypically
masculine (e.g. defend my own beliefs, independent, assertive) and feminine adjectives
(e.g. affectionate, understanding, warm) describe them. Rankings are made on a seven-
point scale (1 = never to almost never true; 7 = always or almost always true). Internal
consistency reliability for the entire scale is generally considered acceptable with
estimates ranging from alpha = .75 to alpha = .87. A recent study confirmed the validity
of the BSRI (Holt, 1998), suggesting that despite recent shifts in gender roles, this
instrument remains a valid measure of sex role stereotypes. Gender role was measured at
both the baseline and three-month follow-up assessments. Total masculine self-image
was the outcome of interest. Estimates of internal consistency reliability were strong at
both the baseline (α = .84) and three-month follow-up (α = .89) assessments.
Catastrophizing. The Hot Flash Catastrophizing Scale (HFCS; see Appendix M)
was developed for use in the current study by modifying the instructions and item content
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of the Fatigue Catastrophizing Scale (FCS; Jacobsen et. al., 1999). The scale consists of
ten items that are designed to assess tendencies to engage in negative self-statements and
overly negative thoughts about the future (i.e. I would tell myself that I didnt think I
could bear the hot flashes any longer.). At the baseline assessment, participants were
asked to indicate on a five-point scale (1 = never true; 5 = all of the time true) how often
they thought each item would be true for them if they were to experience hot flashes. The
instructions for the baseline assessment were worded such that participants were asked to
respond to each item by imagining how they might react if they were to experience hot
flashes. Since the majority of participants had not experienced a hot flash at the first
assessment, they were provided with a commonly cited definition to use as a guide
(Kronenberg, 1994). Internal consistency for this measure in the current study was good
(alpha = .93). At the three-month follow-up assessment, participants were asked to
respond to a slightly different version of the scale that asked them to indicate how they
were currently responding to hot flashes (see Appendix N). Participants who were not
experiencing hot flashes did not complete this measure. Internal consistency reliability
for this version was also good (alpha = .93). Although catastrophizing about hot flashes
has not been investigated, catastrophizing about fatigue has been positively associated
with fatigue severity and negatively associated with quality of life in breast cancer
patients (Broeckel et. al., 1998; Jacobsen et. al., 1999) and catastrophizing about cancer
pain has been found to be positively associated with pain intensity in cancer patients
(Jacobsen & Butler, 1996; Lin, 1998; Wilkie & Keefe, 1991). A total score was derived
by taking the mean of the 10 ratings.
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Quality of life. The Expanded Prostate Cancer Index Composite (EPIC; Wei,
Dunn, Litwin, Sandler, & Sanda, 2000; see Appendix O) is a 22-item measure designed
to measure quality of life issues in men with prostate cancer. It was adapted from the
University of CaliforniaLos Angeles Prostate Cancer Index (UCLA-PCI; Litwin et. al.,
1998) and was expanded to include specific items assessing irritative and obstructive
voiding symptoms, hematuria, additional bowel symptoms, and hormonal symptoms. The
EPIC yields four domain-specific summary scores: urinary, bowel, sexual, and hormonal.
Items are rated using a Likert scale format, with the range of response options dependent
upon the item. Multi-item scale scores can be transformed linearly to a 0 to 100 scale,
with higher scores reflecting better health-related quality of life (HRQOL). Each of the
four domain summary scores exhibit good internal consistency (all alphas > .82) and test-
retest reliability (all r > .80) over a two-week to three-month period. For the purposes of
the current study, the sexual domain summary score will be used as the outcome of
interest. Quality of life was measured at the baseline (alpha = .93) and three-month
follow-up (alpha = .87) assessments with good reliability estimates at each point.
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Results
Participant characteristics
A total of 103 men were invited to participate in the current study. Of those, four
(4%) declined participation, five (5%) were determined to be ineligible, and ten (10%)
were dropped from the study because they did not return their baseline questionnaires
within the allowable time frame. Of the remaining 84 men, four withdrew between the
baseline and three-month follow-up assessments. Data from the remaining 80 men (78%
of those approached) were retained to evaluate the proposed hypotheses. For purpose of
comparison, the 23 men who did not complete the study were grouped together as non-
participants. Participants and non-participants were compared on demographic and
clinical variables to see if the two groups differed in a systematic fashion. No significant
(p < .05) differences were found with regard to any of the demographic or clinical
characteristics assessed. Significance tests for all variables compared can be found in
Table 1.
The 80 men who comprised the final sample ranged from 48 to 90 years of age (M =
72.74, SD = 9.89). They were predominantly Caucasian (88%) and currently married
(78%). The majority had at least a partial college education or specialized training (71%),
were retired (73%), and reported an annual household income of under $40,000 (73%).
See Table 2 for complete demographic information for this sample.
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Table 1
Comparison of demographic and clinical variables between study participants and non-
participants.
Participants
(N = 80)
Non-participants
(N = 23)Variable
n n
statistic p value
Age 72.74
(9.89)
72.65
(10.58)
t = -0.04 .971
Ethnicity χ2 =1.67 .196
Hispanic 9 5
Not Hispanic 71 18
Race χ2 =1.44 .487
White/Caucasian 70 22
Black/African-
American
7 1
Other 3 0
Recruitment Site χ2 =0.31 .578
MCC 23 8
JAHVAH 57 15
Time Since Diagnosis
(years)
2.99
(4.45)
2.32
(3.65)
t = -0.65 .515
Baseline PSA (ng/ml) 22.80
(111.80)
22.18
(33.53)
t = -0.04 .965
LHRH Agonist Used χ2 =0.12 .734
Leuprolide 19 6
Goserelin 61 16
Treatment Category χ2 = 0.12 .944
Primary treatment 22 7
Adjuvant treatment 31 9
Biochemical failure 27 7
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Table 2
Demographic characteristics of the study sample
Variable N = 80
Age (Mean, SD) 72.74 (9.89)
Ethnicity
Hispanic
Not Hispanic
9 (11.3%)
71 (88.8%)
Race
White/Caucasian
Black/African American
Other
70 (87.5%)
7 (8.8%)
3 (3.7%)
Marital Status
Single, never married
Married
Divorced
Widowed
2 (2.5%)
62 (77.5%)
6 (7.5%)
10 (12.5%)
Education
7th grade or less
Junior High School (7th, 8th, & 9th grade)
Partial High School (10th or 11th)
High School Graduate
Partial College or Specialized Training
College or University Graduate
Graduate or professional training
1 (1.3%)
4 (5.0%)
10 (12.5%)
12 (15.0%)
30 (37.5%)
14 (17.5%)
9 (11.3%)
Employment status
Full-time at job
Part-time at job
Disabled
Seeking work
Retired
11 (13.8%)
5 (6.3%)
4 (5.0%)
2 (2.5%)
58 (72.5%)
Total household income
Less than $ 10,000
$10,000 - $19,999
$20,000 - $ 39,999
$40,000 - $59,999
$60,000 - $100,000
Greater than $100,000
Did not report
10 (12.8%)
22 (28.2%)
26 (33.3%)
13 (16.7%)
6 (7.7%)
1 (1.3%)
2 (2.5%)
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Time since prostate cancer diagnosis ranged from day of enrollment in the study
to 18.33 years (M = 2.99, SD = 4.45). Twenty-seven of the men were classified as
biochemical failures (38%) meaning that lab results indicated a steadily rising PSA
despite prior treatment. Of the remaining participants, 22 of the men received an LHRH-
agonist as their primary form of treatment (24%), and the remaining 31 men (39%) were
receiving this form of treatment in addition to or in preparation for another form of
treatment (e.g., prostatectomy or external-beam radiation). Average PSA values at the
time of recruitment ranged from 0.6 ng/mL to over 1000 ng/mL (M=22.80, SD = 111.80).
Three-month follow-up PSA values were available for 67 of the 80 men (84%). At this
time point, average PSA values ranged from below 0.1 ng/mL (undetectable) to 97.40
ng/mL (M=2.34, SD=11.88). Twelve (15%) of the men were prescribed an antiandrogen
agent (bicalutamide) prior to initiation of LHRH-agonists. At the three-month follow-up
assessment, only two of the participants reported that they had sought medication or
herbal remedies to alleviate hot flashes. See Table 3 for complete clinical and treatment
characteristics for this sample.
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Table 3
Clinical characteristics of the study sample
Variable N = 80
Years since diagnosis (Mean, SD) 2.99 (4.45)
LHRH agonist
Leuprolide (Lupron®/ Eligard®)
Goserelin (Zoladex®)
19 (23.8%)
61 (76.3%)
Gleason score at diagnosis
2
5
6
7
8
9
10
Unknown
1 (1.5%)
4 (5.9%)
26 (38.2%)
24 (35.3%)
11 (16.2%)
1 (1.5%)
1 (1.5%)
12 (15.0%)
Prior treatment
Prostatectomy only
Brachytherapy only
External beam radiotherapy only
Combination
None
7 (8.8%)
3 (3.8%)
8 (10.0%)
9 (11.3%)
53 (66.3%)
Concurrent treatment
External beam radiotherapy
Other drugs (i.e. Zometa)
None
18 (22.5%)
3 (3.8%)
59 (73.8%)
Prostate Specific Antigen (PSA (ng/ml)
Baseline (Mean, SD)
3-Month Follow-Up (Mean, SD)
22.8 (111.80)
2.34 (11.88)
Karnofsky (performance status rating)
1: Able to carry on normal activity or do work with no
physical complaints or problems.
2: Able to carry on normal activity or do work even with
minor physical complaints.
3: Able to carry on normal activity or do work with effort
because of physical problems.
4: Unable to carry on normal activity but cares for self.
5: Unable to carry on normal activity and requires occasional
help from others, but is able to care for most of their
personal needs.
17 (21.3%)
28 (35.0%)
20 (25.0%)
5 (6.3%)
8 (10%)
Karnofsky (performance status rating)
6: Requires considerable help from others and requires
frequent medical care.
7: Disabled and requires special care and help.
2 (2.5%)
0 (0.0%)
35
Participants experience of hot flashes
At the baseline assessment, eight of the participants reported experiencing hot
flashes in the previous two weeks. These men had experienced one to four hot flashes
(M=2.13, SD=0.99), with an average severity rating of 2.13 (SD=0.64) on a four-point
scale (1 = mild; 4 = very severe). In order to maintain a homogenous sample in terms of
initial experience with hot flashes, these eight men were dropped from the remainder of
the analyses. Of the remaining 72 men, two could not be reached to complete the six-
week follow-up assessment, but were able to complete the three-month assessment. Of
the 70 men who completed the midpoint assessment, 38 reported experiencing hot flashes
six-weeks after initiation of hormone deprivation therapy (54%). These men reported an
average severity rating of 1.76 (SD=0.82), which most closely corresponds to a moderate
level. The number of hot flashes reported at this time period ranged from one to 154
(M=42.05, SD=46.11) in the previous two weeks. By the three-month follow-up, 50 men
(69%) were reporting hot flashes. The average severity rating had risen to 1.96
(SD=0.76), with the number of hot flashes reported ranging from two to 266 (M=47.26,
SD=51.37) in the previous two weeks. In order to evaluate change in hot flash variables
across time, paired t-tests were performed. Significant increases in hot flash frequency
were noted between the baseline and the midpoint follow-up, t(70)=4.80, p < .0001,
between the midpoint and three-month follow-up, t(70)=2.50, p < .02, and between the
baseline and three-month follow-up, t(72)=5.80, p <.0001. Perceived severity of hot
flashes also increased between the baseline assessment and the midpoint follow-up,
t(70)=7.49, p < .0001, between the midpoint and three-month follow-ups, t(70) = 4.53, p
< .0001, and between the baseline and three-month follow-up, t(72) = 10.46, p <.0001.
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Preliminary analyses
Post-hoc power analyses were conducted for both univariate and multivariate
analyses based upon the sample size of 72. With regard to univariate procedures, power
to detect a medium effect for correlational analyses was .75 (p < .05, two-tailed; r = .30;
Cohen, 1988). Previous research suggests that effects of this magnitude are common with
regard to relationship between adverse symptom states (e.g. pain, fatigue) and
psychological distress. The same sample size was applied to power analysis for multiple
regression analyses with the following assumptions: 1) baseline and follow-up measures
of psychological distress would be correlated at r = .55 or r2 = .30; and 2) the addition of
hot flashes would account for an additional 6% of variability (small to medium effect;
Cohen, 1988) in the outcome of interest (depression or distress) above and beyond the
variance accounted for by baseline values. Power to detect an increment of this
magnitude is .70 with 72 cases.
Prior to analyzing the proposed hypotheses, Spearman rank-order correlations
were computed in order to identify potentially confounding relationships of demographic
and clinical variables with predictor variables, outcome variables, and proposed
mediators or moderators (see Table 4). First, correlations between predictor variables
(hot flash frequency, hot flash severity, hot flash score, and hot flash-related interference)
and demographic and clinical variables were examined. Two significant associations
were noted. Karnofsky Performance Status (a measure of functional impairment) was
negatively associated with hot flash frequency, such that increased frequency of hot
flashes was associated with a lesser degree of impairment (r(72) = -.25, p < .04).
Additionally, the LHRH-agent administered was negatively associated with hot flash-
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Table 4
Correlations between Demographic and Clinical Variables and Predictor Variables
HF Severity HF
Frequency
Variable r p r p
Demographic Variables
Age (years) -.08 .50 -.14 .23
Ethnicity (Hispanic vs. Non-Hispanic) .10 .38 .03 .83
Race (Hispanic vs. Non-Hispanic) .20 .09 .21 .08
Marital Status (married vs. unmarried) .04 .69 .02 .88
Education (HS or less vs. Beyond HS) -.03 .79 -.004 .97
Employment (working vs. not working) .12 .32 .13 .26
Annual Income (under $40,000 vs. over $40,000) .03 .79 .07 .58
Clinical Variables
Time since diagnosis -.05 .67 .04 .75
LHRH agonist (leuprolide vs. goserelin) -.16 .17 -.16 .19
Gleason score at diagnosis .09 .49 .02 .90
Karnofsky Performance Status at baseline -.17 .16 -.25 .04*
Baseline PSA .07 .58 .08 .48
Follow-up PSA -.14 .30 -.06 .65
HF Score
HF-Related
Interference
Variable r p r p
Demographic Variables
Age (years) -.13 .29 -.08 .48
Ethnicity (Hispanic vs. Non-Hispanic) .05 .67 .08 .51
Race (Hispanic vs. Non-Hispanic) .15 .22 .09 .47
Marital Status (married vs. unmarried) .02 .86 -.06 .60
Education (HS or less vs. Beyond HS) -.004 .98 .06 .60
Employment (working vs. not working) .13 .27 -.12 .30
Annual Income (under $40,000 vs. over $40,000) .07 .55 .02 .88
Clinical Variables
Time since diagnosis .02 .85 -.13 .27
LHRH agonist (leuprolide vs. goserelin) -.17 .14 -.23 .05*
Gleason score at diagnosis .03 .83 .01 .93
Karnofsky Performance Status at baseline -.22 .06 .003 .99
Baseline PSA .09 .43 -.08 .50
Follow-up PSA -.07 .59 -.07 .57
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related interference, such that receipt of leuprolide was associated with greater
interference due to hot flashes (r(72) = -.23, p < 05).
Next, relationships among the outcome variables (depressive symptomatology
and cancer-related distress) and demographic and clinical variables were examined.
Participants endorsing a greater number of depressive symptoms were less likely to be
working (r (72) = -.26, p < .03), and reported a greater degree of impairment in daily
functioning (r (72) = .24, p <.04). Relationships with remaining demographic and clinical
variables were not significant (Table 5).
Table 5
Correlations between Demographic and Clinical Variables and Outcome Variables
Depressive
Symptomatology
Cancer-
related
Distress
Variable r p r p
Demographic Variables
Age (years) .004 .97 -.21 .08
Ethnicity (Hispanic vs. Non-Hispanic) -.15 .22 .02 .88
Race (Caucasian vs. Non-Caucasian) -.15 .20 -.01 .91
Marital Status (unmarried vs. married) -.13 .29 -.06 .64
Education (HS or less vs. Beyond HS) -.03 .80 .12 .32
Employment (not working vs. working) -.26 .03* .01 .94
Annual Income (< $40,000 vs. > $40,000) -.18 .14 .05 .65
Clinical Variables
Time since diagnosis -.09 .80 .14 .24
LHRH agonist (leuprolide vs. goserelin) .18 .12 -.08 .52
Gleason score at diagnosis .14 .29 .06 .63
Karnofsky Performance Status at baseline .29 .01* -.09 .44
Baseline PSA -.17 .17 -.14 .24
Follow-up PSA -.03 .80 -.11 .42
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Finally, correlations between the proposed mediators (most fatigue, sleep quality,
sexual functioning) and moderators (masculine gender role and catastrophizing potential)
and demographic and clinical variables were examined. Of the potential mediating
variables, higher levels of most fatigue was associated with unmarried status (r (70) = -
.23, p < .05) and poorer sleep quality was associated with a greater degree of impairment
in daily functioning (r (72) = .24, p < .04). Remaining correlations between demographic
and clinical characteristics and proposed mediating variables can be found in Table 6.
Table 6
Correlations between Demographic and Clinical Variables and Potential Mediating
Variables
Most
Fatigue
Sleep
Problems
Sexual
Functioning
Variable r p r p r p
Demographic Variables
Age (years) .04 .77 .03 .79 -.09 .48
Ethnicity (Hispanic vs. Non-Hispanic) .14 .26 -.18 .13 .12 .32
Race (Caucasian vs. Non-Caucasian) -.04 .76 -.09 .46 .03 .79
Marital Status (unmarried vs. married) -.23 .05* -.03 .77 -.05 .69
Education (HS or less vs. Beyond HS) .02 .88 -.09 .44 .14 .26
Employment (not working vs. working) -.15 .22 -.02 .87 .07 .56
Annual Income (< $40,000 vs. > $40,000) .13 .29 -.10 .40 .07 .60
Clinical Variables
Time since diagnosis -.14 .22 -.07 .54 -.13 .28
LHRH agonist (leuprolide vs. goserelin) .09 .48 .07 .54 -.09 .48
Gleason score at diagnosis .14 .29 .13 .32 .06 .64
Karnofsky Performance Status at baseline .19 .11 .24 .04* .01 .93
Baseline PSA -.15 .23 -.13 .27 .21 .09
Follow-up PSA -.23 .08 -.13 .33 .22 .10
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Of the potential relationships with proposed moderating variables, greater levels
of catastrophizing potential was associated with a longer time since diagnosis (r (71) =
.35, p < .008), higher levels of masculine gender role were associated with having an
annual income of over $40,000 (r (72) = .31, p < .008), longer time since diagnosis (r
(72) = .35, p < .003), a lesser degree of impairment in daily functioning (r (72) = -.34, p <
.004), and being prescribed leuprolide rather than goserelin (r (72) = -.31, p < .003). A
complete listing of these and other relationships can be found in Table 7.
Table 7
Correlations between Demographic and Clinical Variables and Potential Moderating
Variables
Masculine Gender
Role
Catastrophizing
PotentialVariable
r p r p
Demographic Variables
Age (years) -.02 .86 -.02 .90
Ethnicity (Hispanic vs. Non-Hispanic) -.10 .42 .02 .86
Race (Caucasian vs. Non-Caucasian) .06 .64 -.08 .51
Marital Status (unmarried vs. married) -.18 .13 .12 .33
Education (HS or less vs. Beyond HS) .17 .16 .23 .06
Employment (not working vs. working) .07 .59 .11 .36
Annual Income (< $40,000 vs. >
$40,000)
.31 .008* .19 .11
Clinical Variables
Time since diagnosis .35 .003* .31 .008*
LHRH agonist (leuprolide vs. goserelin) -.31 .008* -.14 .26
Gleason score at diagnosis -.21 .11 .05 .74
Karnofsky Performance Status at baseline -.34 .004* .03 .80
Baseline PSA .01 .92 -.16 .19
Follow-up PSA .07 .62 .04 .76
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A variable was considered to be a potential confound if it was significantly associated
with the predictor variable, the outcome variable, and the proposed mediating or
moderating variable. Karnofsky Performance Status (KPS) met these criteria in the
evaluation of sleep disturbance as a mediator of the relationship between hot flash
frequency and depressive symptomatology. Two sets of regression analyses were
conducted both with and without this potentially confounding variable. Neither yielded
significant results (p>.10).
Descriptive statistics were analyzed in order to evaluate overall changes in
psychosocial measures over the three-month study period. Significant declines in
functioning were noted in several areas. Participants scores on the CES-D significantly
increased from baseline (M=9.01, SD=7.59) to the three-month follow-up (M=11.26,
SD=10.11), t(72)=2.32, p < .05. Participants also reported a greater number of sleep
problems between the baseline (M=0.88, SD=0.79) and follow-up assessments (M=1.09,
SD=0.85), t(72)=2.13, p < .05. Declines in sexual functioning were also evident between
baseline (M=35.13, SD=27.03) and three-month follow-up (M=18.43, SD=17.22),
t(68)=-5.59, p < .001. A complete listing of these results can be found in Table 8.
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Table 8
Descriptive and Univariate Statistics for Psychosocial Variables
Variable Range Baseline 3 MonthFollow-Up t p
Depressive
Symptomatology
0-48 9.01 (7.59) 11.26 (10.11) 2.32 .02*
Cancer-Related
Distress
0-90 11.57 (11.39) 9.62 (11.98) -1.38 .17
Sleep Problems 0-3 0.88 (0.79) 1.09 (0.85) 2.13 .04*
Sleep Efficiency 0-100 83.89 (14.24) 81.93 (15.06) -1.00 .32
Most Fatigue 0-10 4.82 (3.30) 4.96 (3.04) 0.43 .67
Sexual
Functioning
0-100 35.13 (27.03) 18.43 (17.22) -5.59 .0001*
Catastrophizing 1-5 1.26 (0.45) 1.36 (06.0) 0.54 .59
Masculine Self-
Image
10-70 50.79 (10.42) 49.31 (11.47) -1.30 .20
Univariate correlations were also calculated in order to determine the associations among
study variables at the baseline and follow-up assessments. These correlations can be
found in Table 9.
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Table 9
Correlation Matrix of Study Variables at Baseline and Three-Month Follow-Up
1 2 3 4 5 6 7
1 HF freq T3 1.0
2 HF sev T3 .71
***
1.0
3 HF score T3 .93
***
.80
***
1.0
4 HFRDIS T3 .62
***
.65
***
.70
***
1.0
5 Catas T1 -.07 .04 -.09 -.07 1.0
6 Catas T3 .55
***
.56
***
.63
***
.83
***
-.09 1.0
7 BEM T1 .11 .11 .14 .12 .07 -.07 1.0
8 BEM T3 -.07 .03 -.01 -.07 .22 -.18 .61
***
9 CES-D T1 -.03 .03 .02 .26
*
.29
**
.42
**
-.23
10 CES-D T3 .17 .10 .20 .44
***
.02 .69
***
-.02
11 IES T1 .29
**
.13 .21 .26 .37
**
.28 -.09
12 IES T3 .26
*
.21 .24
*
.30
**
.44
***
.33
*
-.06
13 PSQI T1 .13 .05 .14 .26
*
.06 .32
*
.03
14 PSQI T3 .35
**
.38
***
.41
***
.51
***
.02 .50
***
.04
15 FSI T1 .15 -.02 .11 .24
*
-.14 .34
**
-.10
16 FSI T2 .17 .15 .22 .42
***
-.08 .46
***
-.02
17 Sex Fxn T1 .10 .04 .05 -.03 -.06 -.01 .001
18 Sex Fxn T3 -.02 .003 .0006 -.01 -.07 -.01 .14
* p < .05
** p < .01
*** p < .001
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Table 9
(continued)
8 9 10 11 12 13 14
8 BEM T3 1.0
9 CES-D T1 -.13 1.0
10 CES-D T3 -.12 .60
***
1.0
11 IES T1 -.03 .39
***
.33
**
1.0
12 IES T3 .09 .53
***
.46
***
.62
***
1.0
13 PSQI T1 -.02 .46
***
.30
*
.15 .33
**
1.0
14 PSQI T3 -.14 .39
***
.45
***
.14 .26
*
.60
***
1.0
15 FSI T1 -.13 .37
**
.37
**
.19 .18 .42
***
.22
16 FSI T2 -.09 .25
*
.47
***
.07 .22 .34
**
.44
***
17 Sex Fxn T1 .18 .01 -.009 -.02 .04 -.12 -.02
18 Sex Fxn T3 .10 -.15 -.07 -.19 -.18 -.10 -.03
Table 9
(continued)
15 16 17 18
15 FSI T1 1.0
16 FSI T2 .45
***
1.0
17 Sex Fxn T1 -.15 -.08 1.0
18 Sex Fxn T3 .009 -.13 .45
***
1.0
* p < .05
** p < .01
*** p < .001
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Relationship between hot flashes and distress
The first set of hypotheses proposed that a worse experience of hot flashes would
be significantly associated with an increase in psychological distress. Before evaluating
the relationship between hot flashes and changes in distress, univariate correlations
between hot flashes and distress at the three-month follow-up were examined. Of the
four hot flash indices (frequency, severity, score, and interference), only hot flash-related
interference was significantly associated with depressive symptomatology, r(70) = .44, p
< .0001. Hot flash frequency, r(70) = .27, p < .03, hot flash score, r(70) = .24, p < .04,
and hot flash-related interference, r(70) = .31, p < .009, were all significantly correlated
with cancer-related distress at this time point. A complete listing of correlations among
these variables can be found in Table 10.
Table 10
Correlations between Hot Flash Variables and Psychological Distress Variables at
Three-Month Follow-Up
CES-D score IES score
Variable
r p r p
Hot Flash Variables
Hot Flash Frequency .17 .16 .27 .03*
Hot Flash Severity .10 .40 .21 .07
Hot Flash Score .20 .10 .24 .04*
Hot Flash-Related Interference .44 .0001* .31 .009*
Analyses were then conducted to test the hypothesis that men reporting worse
experiences with hot flashes would experience greater increases in psychological distress
over the three-month study period. Specifically, baseline levels of distress were entered
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on the first step in hierarchical regression analyses in order to create a residualized
change score. Each of the hot flash variables was then entered on the second step in four
separate regression equations. As shown in Table 11, depressive symptomatology
measured prior to initiation of androgen-deprivation therapy accounted for 36% of the
variance in depressive symptomatology measured at the three-month follow-up (p <
.0001). Hot flash-related interference accounted for an additional 8% of the remaining
variance in this variable (p = .002). Although none of the remaining hot flash variables
met the criteria set for significance (p < .05), hot flash frequency (p=.0533) and hot flash
score (p=.0530) both approached significance, each accounting for an additional 3% of
the variance in depressive symptomatology when evaluated independently.
Table 11
Regression Analyses of Hot Flash Variables on Depressive Symptomatology at Three-
Month Follow-Up
Variable β R2 change Cumulative R2 p value
Equation #1
1. Baseline CES-D Score .52 .36 .0001*
2. Hot Flash-Related Interference .30 .08 .44 .0020*
Equation #2
1. Baseline CES-D Score .61 .36 .0001*
2. Hot Flash Frequency .19 .03 .39 .0533
Equation #3
1. Baseline CES-D Score .60 .36 .0001*
2. Hot Flash Severity .08 .01 .37 .3958
Equation #4
Baseline CES-D Score .60 .36 .0001*
Hot Flash Score .19 .03 .39 .0530
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To better understand the relative contributions of each measure of hot flash
experience, exploratory regression analyses were conducted, entering all four of the hot
flash variables simultaneously. Hot flash-related interference entered the model first,
accounting for 8% of the variance in changes in depressive symptomatology (p = .002).
None of the remaining three measure of hot flash experience accounted for additional
variance in changes in depression (ps > .05).
Identical procedures were followed in order to determine the ability of hot flashes
to predict changes in cancer-related distress over the three-month study period. As shown
in Table 12, baseline reports of cancer-related distress accounted for 39% of the variance
in cancer-related distress measured three months later (p < .0001). None of the four
measures of hot flash experience accounted for significant proportions of the remaining
variance (ps > .10).
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Table 12
Regression Analyses of Hot Flash Variables on Cancer-Related Distress at Three-Month
Follow-Up
Variable β R2 change Cumulative R2 p value
Equation #1
1. Baseline IES Score .58 .39 .0001*
2. Hot Flash-Related Interference .15 .02 .41 .1185
Equation #2
1. Baseline IES Score .59 .39 .0001*
2. Hot Flash Frequency .10 .01 .39 .3358
Equation #3
1. Baseline IES Score .60 .39 .0001*
2. Hot Flash Severity .14 .02 .40 .1510
Equation #4
1. Baseline IES Score .60 .39 .0001*
2. Hot Flash Score .11 .01 .40 .2366
Relationship between hot flashes and fatigue, sleep problems, and sexual functioning
The second set of hypotheses proposed that a worse experience of hot flashes
would be associated with greater increases in fatigue, poorer sleep quality, and greater
declines in sexual functioning over the three-month study period. As with the first set of
hypotheses, univariate relationships between each of the variables at the final assessment
point were examined prior to conducting hierarchical regression analyses (see Table 13).
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Table 13
Correlations between Hot Flash Variables and Fatigue, Sleep Problems, and Sexual
Functioning at Three-Month Follow-Up
Most
Fatigue
Sleep
Problems
Sexual
FunctioningVariable
r p r p r p
Hot Flash Frequency .17 .15 .35 .003* -.02 .86
Hot Flash Severity .15 .22 .39 .0008* .003 .98
Hot Flash Score .22 .06 .41 .0004* .0006 .99
Hot Flash-Related Interference .42 .0004* .51 .0001* -.01 .94
Ratings of most fatigue at the three-month follow-up were significantly associated
with hot flash-related interference, r(70)=.42, p < .0001, but were not significantly
associated with any of the remaining hot flash variables. In order to test the hypothesis
that men reporting worse experiences with hot flashes would also experience greater
increases in fatigue, hierarchical regression analyses were conducted using the same
procedures as described above. As shown in Table 14, baseline levels of most fatigue
measured prior to initiation of androgen-deprivation therapy accounted for 21% of the
variance in ratings of most fatigue three months later (p < .0001). Hot flash-related
interference accounted for an additional 10% of the variance in ratings of most fatigue (p
< .003). None of the three remaining hot flash variables accounted for a significant
portion of the remaining variance.
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Table 14
Summary of Regression Analyses of Most Fatigue at Three-Month Follow-Up
Variable β R2 change Cumulative R2 p value
Equation #1
1. Baseline Most Fatigue .37 .21 .0001*
2. Hot Flash-Related Interference .32 .10 .32 .0032*
Equation #2
1. Baseline Most Fatigue .44 .21 .0001*
2. Hot Flash Frequency .11 .01 .22 .3365
Equation #3
1. Baseline Most Fatigue .46 .21 .0001*
2. Hot Flash Severity .16 .03 .23 .1465
Equation #4
1. Baseline Most Fatigue .43 .21 .0001*
2. Hot Flash Score .17 .03 .23 .1139
Poorer sleep quality was associated with hot flash frequency, r(72)= .35, p < .003,
hot flash severity, r(72)= .39, p < .0008, hot flash score, r(72)= .41, p < .0004, and hot
flash-related interference r(72)= .51, p < .0001. Hierarchical regression analyses were
then conducted to evaluate the ability of hot flashes to predict decreases in sleep quality.
As shown in Table 15, baseline levels of sleep problems accounted for 36% of the
variance in sleep quality three months after initiation of androgen deprivation therapy (p
< .0001). Each of the four measures of hot flash experience accounted for additional
variance in ratings of sleep quality at the three-month follow-up assessment when
evaluated independently (ps < .0004). Hot flash-related interference and hot flash
severity accounted for the largest amounts, each accounting for 13% additional variance,
followed by hot flash score (11%), and hot flash frequency (8%). For exploratory
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purposes, the ability of hot flash variables to predict changes in habitual sleep efficiency
was also evaluated using regression analyses. None of the four indices of hot flash
experience explained additional variance in sleep efficiency at the three month-follow up
above and beyond baseline levels of sleep efficiency (ps > .05).
Table 15
Summary of Regression Analyses of Sleep Problems at Three-Month Follow-Up
Variable β R2 change Cumulative R2 p value
Equation #1
1. Baseline Sleep Problems .50 .36 .0001*
2. Hot Flash-Related Interference .38 .13 .49 .0001*
Equation #2
1. Baseline Sleep Problems .56 .36 .0001*
2. Hot Flash Frequency .28 .08 .44 .0035*
Equation #3
1. Baseline Sleep Problems .58 .36 .0001*
2. Hot Flash Severity .36 .13 .49 .0001*
Equation #4
1. Baseline Sleep Problems .55 .36 .0001*
2. Hot Flash Score .33 .11 .47 .0004*
Sexual functioning was not significantly associated with any of the four indices of
hot flash experience in correlational analyses (ps > .05). Baseline levels of sexual
functioning accounted for 20% of the variance in sexual functioning three months later (p
< .0001); however, none of the hot flash variables accounted for additional variance (see
Table 16).
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Table 16
Summary of Regression Analyses of Sexual Functioning at Three-Month Follow-Up
Variable β R2 change Cumulative R2 p value
Equation #1
1. Baseline Sexual Functioning .45 .20 .0001*
2. Hot Flash-Related Interference .006 .000 .20 .9928
Equation #2
1. Baseline Sexual Functioning .45 .20 .0001*
2. Hot Flash Frequency -.03 .001 .20 .8094
Equation #3
1. Baseline Sexual Functioning .45 .20 .0001*
2. Hot Flash Severity .000 .20 .9911
Equation #4
1. Baseline Sexual Functioning .45 .20 .0001*
2. Hot Flash Score .005 .000 .20 .9644
Relationship between Fatigue, Sleep Problems, Sexual Functioning and Psychological
Distress
The third set of hypotheses proposed that men experiencing greater increases in
fatigue, sleep problems, and sexual impairment would report greater increases in
depressive symptomatology and cancer-related distress. As with the previous two sets of
hypotheses, univariate correlations will be presented first (Table 17) followed by the
results of hierarchical regression analyses.
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Table 17
Correlations between Psychological Distress Variables and Fatigue, Sleep Problems,
and Sexual Functioning at Three-Month Follow-Up
Depressive
Symptomatology
Cancer-related
DistressVariable
r p r p
Most Fatigue .47 .0001* .22 .07
Sleep Problems .45 .0001* .26 .03*
Sexual Functioning -.07 .56 -.18 .14
Ratings of depressive symptomatology at the three-month follow-up assessment
were significantly correlated with ratings of most fatigue, r(70)=.47, p < .0001, and sleep
problems at the same time point, r(72)=.45, p < .0001. Sexual functioning was not
associated with depressive symptomatology (p > .05).
In order to evaluate this set of hypotheses, baseline levels of depressive
symptomatology and baseline levels of the variable of interest (most fatigue, sleep
problems, sexual functioning) were forced into the equation on the first step. Participants
rating of the variable of interest at the follow-up assessment was then entered on the
second step, in order to determine the unique contribution of change occurring during the
three-month study period. Taken together, ratings of depressive symptomatology and
most fatigue made prior to initiation of androgen deprivation therapy accounted for 39%
of the variance in depressive symptomatology three months later (p < .0001). Ratings of
most fatigue at the three-month follow-up accounted for an additional 9% of the variance
in depressive symptomatology at this same point (p < .0016).
In a separate regression equation, baseline depressive symptomatology and
baseline sleep quality accounted for 36% of the variance in depressive symptomatology
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three months later (p < .0001). The addition of sleep quality measured at the three-month
follow-up accounted for an additional 7% of the variance (p < .0064). Post-treatment
ratings of sexual functioning did not account for additional variance in post-treatment
levels of depressive symptomatology when examined in this fashion (p > .05). These
results are shown in Table 18.
Table 18
Regression Analyses of Potential Mediators on Depressive Symptomatology at Three-
Month Follow-Up
β R2 change Cumulative R2 p value
Equation #1
1. Baseline CES-D Score .50 .0001*
Baseline Most Fatigue .04 .39 .0854
2. 3-Month Most Fatigue .33 .09 .48 .0016*
Equation #2
1. Baseline CES-D Score .54 .0001*
Baseline Sleep Problems -.14 .36 .7776
2. 3-Month Sleep Problems .33 .07 .43 .0064*
Equation #3
1. Baseline CES-D Score .62 .0001*
Baseline Sexual Functioning -.04 .37 .8327
2. 3-Month Sexual Functioning .05 .002 .37 .6356
Similar procedures were used in order to determine the relative contribution of
changes in fatigue, sleep quality, and sexual functioning to changes in cancer-related
distress. Initially, univariate correlations were examined. As shown in Table 17, cancer-
related distress was significantly associated with sleep quality three months after
initiation of androgen deprivation therapy, such that higher levels of cancer-related
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distress was associated with poorer sleep quality, r(72)=.26, p < .03. The relationship
between cancer-related distress and most fatigue approached significance, r(70)=.22,
p=.07. Sexual functioning was not a significant correlate of cancer-related distress (p >
.05).
Taken together, baseline ratings of cancer-related distress and most fatigue
accounted for 39% of the variance in cancer-related distress at the three-month follow-up
assessment (p < .0001). Levels of most fatigue at the three-month follow up accounted
for an additional 3% of the variance in baseline levels of cancer-related distress; however,
this did not meet the criteria set for significance (p = .07). Neither sleep problems nor
sexual functioning accounted for additional variance in cancer-related distress after
accounting for baseline levels (ps > .05). These results appear in Table 19.
Table 19
Regression Analyses of Potential Mediators on Cancer-Related Distress at Three-Month
Follow-Up
β R2 change Cumulative R2 p value
Equation #1
1. Baseline IES Score .62 .0001*
Baseline Most Fatigue -.03 .39 .5613
2. 3-Month Most Fatigue .19 .03 .42 .0731
Equation #2
1. Baseline IES Score .58 .0001*
Baseline Sleep problems .21 .44 .0098*
2. 3-Month Sleep problems .06 .002 .45 .6190
Equation #3
1. Baseline IES Score .59 .0001*
Baseline Sexual Functioning .09 .37 .6254
2. 3-Month Sexual Functioning -.10 .008 .38 .3891
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Tests of Mediation
In order to test for mediation, three conditions must be met (Baron and Kenney,
1986). First, the predictor variable must be associated as hypothesized with the outcome
variable (Figure 1; Path c). It was hypothesized that a worse hot flash experience would
be associated with greater increases in depressive symptomatology and cancer-related
distress over the three-month period. The predictor variable of interest, hot flashes, was
measured in four ways (frequency, severity, score, and interference). As can be seen in
Tables 11, of the four indices of hot flash experience, only hot flash-related interference
was significantly associated with changes in depressive symptomatology. None of the
four hot flash variables accounted for significant variance in changes in cancer-related
distress (see Table 12). Based upon these results and application of the criterion, hot
flash-related interference will serve as the sole predictor variable and depressive
symptomatology will serve as the outcome variable.
The second condition requires that the predictor variable is associated as
hypothesized with the mediator (Figure 1; Path a). Three potential mediators were
evaluated: changes in sleep problems, most fatigue, and sexual functioning. It was
hypothesized that greater hot flash-related interference would be associated with
decreases in sleep quality and sexual functioning, and increases in levels of most fatigue
over the three month period. Regression analyses indicate that hot flash-related
interference accounted for significant variance in both most fatigue (Table 14) and sleep
quality (Table 15) after accounting for baseline levels of each variable. Hot flash-related
interference failed to account for significant variance in changes in sexual functioning
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(Table 16). Consequently, only most fatigue and sleep quality met this criterion for
mediation.
The third condition requires that the mediator is associated as hypothesized with
the outcome variable (Figure 1; Path b). It was hypothesized that greater increases in
most fatigue and greater decreases in sleep quality and sexual functioning would be
associated with greater increases in depressive symptomatology over the three-month
period. As shown in Table 18, changes in both sleep problems and most fatigue emerged
as significant contributors to changes in depressive symptomatology.
Based on the findings outlined above, changes in most fatigue and sleep quality
were evaluated as potential mediators of the relationship between hot flash-related
interference and depressive symptomatology. In order to be considered a mediator,
inclusion of these variables in regression analyses must significantly reduce or eliminate
the relationship between the predictor variable (hot flash-related interference) and the
outcome variable (depressive symptomatology).
Most fatigue
Sleep problems
a b
Hot flash-related interference Depressive symptomatology
c
Figure 1. Model of the Relationship between HotFlash-Related Interference and
Depressive Symptomatology as Mediated by Most Fatigue and Sleep Problems
As shown in Table 20, after accounting for changes in most fatigue, hot flash-
related interference failed to account for a significant proportion of the variance in
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change in depressive symptomatology (p = .06). A test of the indirect effect of hot flash-
related interference on changes in depression via changes in most fatigue was assessed
using the Sobel (1982) test as described by Baron and Kenny (1986). Results indicated
that this reduction was due to a significant mediation effect of fatigue on hot flash-related
interference (z = 1.97, p < .05).
Table 20
Evaluation of Changes in Most Fatigue and Sleep Problems as Mediators of the
Relationship between Hot Flash-Related Interference and Changes in Depression
β R2 change Cumulative R2 p value
Equation #1
1. Baseline CES-D Score .47 .0001*
Baseline Most Fatigue .04 .7246
Three-Month Most Fatigue .26 .47 .0147*
2. Hot Flash-Related Interference .19 .03 .50 .0553
Equation #2
1. Baseline CES-D Score .51 .0001*
Baseline Sleep Problems -.12 .3104
Three-Month Sleep Problems .21 .43 .1037
2. Hot Flash-Related Interference .23 .04 .46 .0334*
Similar analyses were repeated entering changes in sleep quality as the potential
mediator. Hot flash-related interference remained a significant predictor of changes in
depression after controlling for changes in sleep quality, accounting for 4% of the
variance in this variable (p = .03). Prior to including this variable in the regression
equation, hot flash-related interference accounted for 8% of the variance in changes in
depression. Therefore, the inclusion of sleep quality represents a 50% reduction in
variance accounted for by hot flash-related interference. The follow-up Sobel test
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confirms that sleep quality did not completely mediate the relationship between hot flash-
related interference and depressive symptomatology (z = 1.49, p > .10).
Tests of Moderation
The final two sets of hypotheses proposed that catastrophizing potential and
masculine self-image would moderate the relationship between hot flashes and
psychological distress. Specifically, it was proposed that the combination of higher levels
of catastrophizing and a worse hot flash experience would be associated with higher
levels of cancer-related distress and depression. Additionally, it was anticipated that the
combination of higher levels of masculine self-image and a worse hot flash experience
would be associated with higher levels of cancer-related distress and depression.
In order to determine if either masculine self-image or catastrophizing potential
moderated the relationship between hot flashes and depression, hierarchical regression
analyses were conducted. In each equation, baseline levels of depression were entered
first in order to create a residualized change score. This was followed by one of the four
hot flash variables, then by either catastrophizing potential or masculine self-image, and
then by the appropriate interaction term. Each of the predictor variables and potential
moderating variables were centered in order to reduce multicollinearity (Aiken & West,
1991). In this study, each of the hot flash variables, catastrophizing potential, and
masculine self-image were centered by subtracting the mean of the respective variable
from each participants score on that variable. As shown in Tables 21 and 22, neither
masculine self-image nor catastrophizing potential were significant moderators of the
relationship between hot flashes and depressive symptomatology.
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Table 21
Evaluation of Masculine Self-Image as a Moderator of the Relationship between Hot
Flash Experience and Depressive Symptomatology
β R2 change Cumulative R2 p value
1. Baseline Depression .65 .0001*
Hot Flash Frequency (A) .15 .1203
Masculine Self-Image (B) .08 .40 .4114
2. A x B -.11 .01 .41 .2552
1. Baseline Depression .64 .0001*
Hot Flash Severity (A) .06 .5449
Masculine Self-Image (B) .09 .38 .3606
2. A x B -.16 .03 .40 .0948
1. Baseline Depression .65 .0001*
Hot Flash Score (A) .17 .0710
Masculine Self-Image (B) .07 .40 .5122
2. A x B -.14 .02 .42 .1565
1. Baseline Depression .54 .0001*
HF-Related Interference (A) .32 .0014*
Masculine Self-Image (B) .03 .45 .7211
2. A x B -.17 .03 .48 .0650
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Table 22
Evaluation of Catastrophizing Potential as a Moderator of the Relationship between Hot
Flash Experience and Depressive Symptomatology
β R2 change Cumulative R2 p value
1. Baseline Depression .65 .0001*
Hot Flash Frequency (A) .15 .1711
Catastrophizing Potential (B) -.16 .41 .1212
2. A x B -.04 .001 .42 .7443
1. Baseline Depression .64 .0001*
Hot Flash Severity (A) .09 .3713
Catastrophizing Potential (B) -.17 .39 .1071
2. A x B .02 .0003 .39 .8535
1. Baseline Depression .64 .0001*
Hot Flash Score (A) .15 .1812
Catastrophizing Potential (B) -.15 .41 .1418
2. A x B -.03 .0007 .41 .7768
1. Baseline Depression .54 .0001*
HF-Related Interference (A) .30 .0215*
Catastrophizing Potential (B) -.10 .45 .3575
2. A x B .04 .0009 .46 .7387
Comparable regression analyses were then conducted to determine if either
masculine self-image or catastrophizing potential moderated the relationship between hot
flashes and cancer-related distress. As shown in Table 23, masculine self-image did not
moderate the relationship between hot flash experience and cancer-related distress (ps >
.05).
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Table 23
Evaluation of Masculine Self-Image as a Moderator of the Relationship between Hot
Flash Experience and Cancer-Related Distress
β R2 change Cumulative R2 p value
1. BL Cancer-Related Distress .58 .0001*
Hot Flash Frequency (A) .12 .2305
Masculine Self-Image (B) .01 .39 .9460
2. A x B .11 .01 .41 .2637
1. BL Cancer-Related Distress .59 .0001
Hot Flash Severity (A) -.01 .1437
Masculine Self-Image (B) .14 .40 .9082
2. A x B .04 .002 .40 .6473
1. BL Cancer-Related Distress .59 .0001
Hot Flash Score (A) .12 .2331
Masculine Self-Image (B) .02 .40 .8414
2. A x B .16 .02 .42 .1014
1. BL Cancer-Related Distress .58 .0001*
HF-Related Interference (A) .13 .1951
Masculine Self-Image (B) .03 .41 .7570
2. A x B .14 .02 .43 .1634
A different pattern of results emerged when evaluating catastrophizing potential
as a moderator. Each of the four indices of hot flashes (frequency, severity, score, and
interference) was evaluated as an independent predictor of distress. As shown in Table
24, there were significant main effects for hot flash-related interference (β = .38, t = 3.69,
p < .0005) and catastrophizing potential (β = .42, t = 4.16, p < .0001).
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Table 24
Evaluation of Catastrophizing Potential as a Moderator of the Relationship between Hot
Flash Experience and Cancer-Related Distress
β R2 change Cumulative
R2
p value
1. BL Cancer-Related Distress .47 .0001*
Hot Flash Frequency (A) .27 .0175*
Catastrophizing Potential (B) .31 .46 .0024*
2. A x B .21 .03 .49 .0510
1. BL Cancer-Related Distress .51 .0001*
Hot Flash Severity (A) .12 .2201
Catastrophizing Potential (B) .27 .46 .0124*
2. A x B -.07 .004 .46 .4948
1. BL Cancer-Related Distress .47 .0001*
Hot Flash Score (A) .28 .0115*
Catastrophizing Potential (B) .32 .47 .0018*
2. A x B .20 .03 .49 .0621
1. BL Cancer-Related Distress .40 .0001*
HF-Related Interference (A) .38 .0005*
Catastrophizing Potential (B) .42 .48 .0001*
2. A x B .32 .07 .55 .0024*
In addition, the interaction between hot flash-related interference and
catastrophizing was also significant (β = .32, t = 3.16, p < .0024). In order to interpret
this significant interaction, three simple lines of the regression of cancer-related distress
(y) on hot flash interference (x) as a function of three values of catastrophizing potential
(see Figure 2). These three values correspond to one standard deviation above the mean,
the mean, and one standard deviation below the mean.
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Figure 2. Effect of Hot Flash-Related Interference on Cancer-Related Distress by
Catastrophizing Potential
The slope of the cancer-related distress scores was significantly different from
zero for high (slope = .63, t = 2.68, p < .01) and mean levels (slope = .29, t = 2.90, p <
.01) of catastrophizing potential, but not for low levels (slope = -.05, t = 0.47, p > .05).
These results suggest that catastrophizing potential moderates the relationship between
hot flash-interference and cancer-related distress. Specifically, men who did not
anticipate that they would catastrophize in response to hot flashes exhibited uniformly
low levels of cancer-related distress, regardless of the level of interference in daily
activities due to hot flashes. In contrast, men with greater potential to engage in
catastrophizing in response to hot flashes exhibited low levels of distress with low levels
of hot flash-related interference, but high levels of distress with high levels of hot flash-
related interference.
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Discussion
The goal of the current study was to increase our understanding of mens
experience of hot flashes while receiving androgen deprivation therapy for prostate
cancer. Hot flashes are an unusual experience for most men and little is known about
their impact on psychological functioning and quality of life. The current study
hypothesized that the experience of hot flashes in this population would lead to increased
distress. Results were partially consistent with this hypothesis. The degree to which hot
flashes interfered with patients ability to engage in their daily activities predicted
increases in depressive symptomatology over the three-month study period; however,
none of the four hot flash variables (frequency, severity, score, interference) were
successful in predicting changes in cancer-related distress.
In addition to reports of increased psychological distress, it was expected that men
reporting a worse experience of hot flashes would also report greater sleep disturbance,
fatigue, and sexual dysfunction. All four indices of hot flash experience predicted
increased sleep disturbance. Hot flash-related interference was the only variable to
predict increases in levels of most fatigue. There was no evidence to support the
hypothesis that a worse experience of hot flashes lead to increased sexual dysfunction.
In an effort to further understand the relationship between hot flashes and distress,
we evaluated potential mediators of this relationship. Results partially supported the
hypothesized mediational models. That is, increases in fatigue were found to mediate the
relationship between hot flash-related interference and depressive symptomatology;
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however, this variable did not mediate the relationship between hot flashes and cancer-
related distress. Sexual dysfunction did not mediate any of the proposed relationships.
The final set of hypotheses proposed that catastrophizing potential and masculine
self-image would serve as moderators of the relationship between hot flash experience
and psychological distress. These hypotheses were partially supported. Catastrophizing
potential was found to moderate the relationship between hot flash-related interference
and cancer-related distress. For men who reported high levels of catastrophizing
potential, subsequent levels of cancer-related distress were dependent upon the degree to
which hot flashes interfered with functioning. Men who reported low levels of
catastrophizing potential experienced low levels of cancer-related distress regardless of
the degree to which hot flashes interfered with their daily functioning.
The following discussion will place these findings in context with the existing
literature and highlight the ways in which they further our understanding of the
psychological impact of hot flashes in men. Potential clinical implications of these
findings will be discussed in relation to the treatment of hot flashes. Finally, limitations
of the current study will be outlined along with suggestions for future research.
These findings add to the growing body of research documenting a relationship
between receipt of androgen deprivation therapy and psychological distress (Fowler, et.
al., 2002; Herr & OSullivan, 2000; Pirl, et. al., 2002). To date, most studies conducted
with men on androgen deprivation therapy have not attempted to differentiate among the
constellation of side effects that occur as a result of this form of treatment. Of particular
interest in the current study was the impact of hot flashes on increases in distress over the
three-month period following the initiation of androgen deprivation therapy. Although
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other studies have found strong relationships between frequency and/or severity of hot
flashes and measures of psychological distress in women with breast cancer, (Carpenter
et. al., 1998; Carpenter, et. al., 2002), these relationships were not as well defined in men
with prostate cancer. In the present study, ratings of hot flash-related interference
emerged as the sole significant predictor of increases in depression. This suggests that the
extent to which hot flashes interfere with patients daily functioning may be more
important to evaluate than the frequency or severity of hot flashes in identifying men at
risk for depression. Since the studies conducted to date have not typically examined this
relationship in a longitudinal fashion, it is difficult to make direct comparisons to
previous literature. Of relevance are cross-sectional studies showing that hot flash-related
interference is positively correlated with negative affect and mood disturbance in women
with breast cancer (Carpenter, 2001) and poorer quality of life in men with prostate
cancer (Nishiyama, et. al, 2004).
As noted previously, changes in sexual functioning failed to account for
significant variance in either depression or cancer-related distress. In comparison, hot
flash-related interference accounted for significant variance in depressive
symptomatology over the three month study period. Taken together, these findings
suggest that interference due to hot flashes may play a larger role in the development and
maintenance of depressive symptoms than sexual problems. Along with hot flashes,
sexual dysfunction is considered to be one of the more prevalent and upsetting side
effects for men receiving androgen deprivation therapy (Fowler, et. al., 2002; Herr &
OSullivan, 2000; Potosky, et. al., 2001 Potosky, et. al., 2002); however the origins of
sexual dysfunction in this population are likely to be multifactorial. Prior treatments for
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prostate cancer (i.e. prostatectomy, radiation), comorbid health conditions, and side
effects from various medications are all potential contributors to the development of
sexual dysfunction. Impairment in sexual functioning may pre-date the initiation of
androgen deprivation therapy for many of these men; therefore the current study may not
have captured the initial distress associated with this loss in functioning.
Results of the current study provide evidence in support of potential mechanisms
by which hot flash-related interference contributes to increases in depression. Level of
fatigue reported by these men mediated the relationship between hot flashes and
depression. No other studies can be identified that have attempted to explore potential
mediators of the relationship between hot flashes and distress in men or women.
However, consistent with the current results, fatigue has been linked to hot flashes in
cross-sectional studies of women with breast cancer (Carpenter, et. al., 2004; Stein, et. al.
2000).
The impact of hot flash-related interference on cancer-related distress does appear
to differ as a function of use of catastrophizing as a coping tool. Results suggest that the
cancer-related distress of men reporting greater use of catastrophizing appears to increase
as hot flash-related interference increases. Men low in expected use of catastrophizing
exhibit consistently low levels of cancer-related distress regardless of hot flash-related
interference. These findings are line with the body of literature supporting a strong
association between use of catastrophizing and increased ratings of pain (Sullivan, Thorn,
Haythornthwaite, et. al., 2001). Prospective ratings of catastrophizing have been found to
predict subsequent ratings of pain in response to dental procedures and in individuals
with arthritis (Keefe, et.al., 1989; Sullivan, Bishop, & Pivik, 1995; Sullivan & Neish,
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1999). A similar pattern has been found in relation to the experience of fatigue in cancer
patient populations. In women with breast cancer, catastrophizing has been found to
predict more severe fatigue in response to radiation therapy (Jacobsen, Andrykowski, &
Thors, 2004). Taken together, these findings support the notion that reliance on
catastrophizing as a coping mechanism can lead to a more intense experience of
symptoms.
Although this study represents an advance over much of the previous cross-
sectional research on hot flashes in prostate cancer patients, certain limitations should be
considered when evaluating the results. First, because this is the initial study to
longitudinally evaluate the role of hot flashes in the development of distress, the results
should be considered preliminary and in need of replication. Because the sample size was
relatively small, the ability of these results to generalize to the broad population of
prostate cancer patients is unknown. Despite the small sample size, however, the
demographic make-up was fairly diverse in terms of ethnicity and income.
Second, the present study used subjective ratings of hot flash presence, frequency,
and severity. The fact that these self-report ratings of hot flashes were made
retrospectively introduces an element of recall bias. Although some investigations utilize
daily diaries in order to combat this problem (Carpenter, et. al., 2001; Sloan, et. al.,
2001), non-adherence and missing data were of significant concern with this population.
Although objective physiological assessment tools such as sternal skin conductance
monitoring can be used to measure hot flashes (Carpenter, Andrykowski, Freedman, &
Munn, 1999; Carpenter, Monahan, & Azzouz, 2004; Coyne, 2005), this form of
assessment is not without its limitations. A recent report by the National Institutes of
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Health points out that sternal skin conductance monitoring fails to capture important
information such as perceived severity and interference with daily activities (Miller & Li,
2004). This method also poses considerable burden on research participants, requiring
frequent home visits by study personnel to adjust the equipment and read the data, as well
as potential discomfort with electrodes.
It should also be noted that the hot flash variables (predictors), distress variables
(outcomes), and potential mediators and moderators were assessed concurrently;
therefore, causal relationships among these variables cannot be conclusively determined.
Incorporation of daily diaries or real-time data collection technology (e.g. palm-sized
data recording devices) would more accurately allow for evaluation of the temporal
relationship between hot flashes, fatigue, and psychological distress. This type of
repeated assessment would more clearly demonstrate the relationship between the onset
of hot flashes and subsequent development of fatigue and depression.
A third limitation of the current study was the heterogeneity of the sample in
terms of stage of illness, time since diagnosis, and treatment history. These men were at
different stages of their disease trajectory and therefore may not have been responding to
the onset of a new set of side effects in the same manner. Men who had been living with a
prostate cancer diagnosis for a number of years may have been less distressed by hot
flashes, as they may have had time to adjust to the limitations imposed by prostate cancer
and its treatment. Despite this apparent diversity, time since diagnosis did not prove to be
a significant correlate of psychological distress or any of the hot flash variables.
Studies have shown that hot flashes do not generally subside as time since
treatment increases (Karling, Hammar & Varenhorst, 1994; Spetz, et. al., 2001);
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therefore, it is important to recognize the impact of this treatment-related side effect and
to develop appropriate and effective remedies. Preliminary evidence lends support to the
use of pharmacological agents in reducing hot flashes in men, including megestrol
acetate, a synthetic progesterone (Loprinzi, et. al., 1994), as well as anti-depressants such
as paroxetine (Loprinzi, et. al., 2004) and venlafaxine (Quella, et. al., 1999). Despite their
apparent success in reducing the incidence of hot flashes, these medications come with
their own set of side effects; including nausea, dry mouth, decreased appetite, and
constipation. Furthermore, a well documented placebo effect in hot flash studies
estimates a 20-30% reduction in hot flash score with four weeks of a placebo (Sloan, et.
al., 2001). The substantial placebo effect and potentially aversive side effects from
pharmacological agents speak to the need for behavioral interventions designed to reduce
hot flashes.
Results of the present study suggest several additional avenues for clinical
intervention. Fatigue and catastrophizing, in particular, appear to be promising areas of
exploration. Results of mediation analysis suggest that reducing fatigue would
significantly decrease or eliminate the relationship between hot flash-related interference
and increased symptoms of depression. Routine physical activity has long been regarded
as an effective method of enhancing mood, sleep quality, and overall quality of life. A
recent study has examined the utility of exercise in a prostate cancer population (Segal,
Reid, Courneya, et. al., 2003). In a sample of in men receiving androgen deprivation,
participation in a 12-week resistance exercise program led to improvements in symptoms
of fatigue and quality of life relative to a wait list control condition. This initial
investigation lends further support to the beneficial qualities of physical activity;
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however, a highly structured program such as this may not be feasible in many outpatient
settings. Future studies should explore the efficacy of less intensive interventions that
would generalize to a broader range of settings.
Results further indicate that use of catastrophizing may determine the amount of
cancer-related distress experienced by the patient. This has several implications for
clinical practice. Assessment of catastrophizing may be useful in identifying prostate
cancer patients at risk for developing high levels of cancer-related distress while
receiving androgen deprivation therapy. This can be accomplished by having the patient
complete a brief 10-item measure prior to the initiation of treatment. Patients identified as
prone to catastrophizing may benefit from a brief psycho-educational intervention
designed to promote use of more adaptive coping responses. Results of a recent
randomized controlled trial incorporating both active physical treatment and cognitive-
behavioral treatment was effective in reducing pain catastrophizing in a sample of
patients with nonspecific chronic low back pain (Smeets, Vlaeyen, Kester, & Knottnerus,
2006). Change in pain catastrophizing was found to mediate the reduction of disability,
pain complaints, and pain intensity. Similar interventions designed to reduce hot flash
catastrophizing may result in lower levels of cancer-related distress.
The findings presented here represent an important first step towards
understanding the role of hot flashes in the development of psychological distress in men
receiving androgen deprivation therapy for prostate cancer. Prevalence rates of
depression in this population are thought to be around 12-13% (Pirl, et. al., 2002).
Therefore, it is important to understand the factors that contribute to and maintain these
symptoms. The extent to which hot flashes interfere with the patients ability to engage in
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routine daily activities appears to be the most significant factor in determining increases
in depressive symptomatology. Results of mediation analyses suggest that increased
fatigue partially explains the relationship between hot flash-related interference and
symptoms of depression in men receiving this form of treatment for prostate cancer.
Furthermore, the coping strategy of catastrophizing appears to moderate the relationship
between hot flash-related interference and increases in cancer-related distress. Additional
research is needed to realize the potential of these findings in clinical populations.
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Appendix A: Informed Consent for Moffitt Cancer Center
Informed Consent
Social and Behavioral Sciences
University of South Florida
Information for People Who Take Part in Research Studies
The following information is being presented to help you decide whether or not you want
to take part in a minimal risk research study. Please read this carefully. If you do not
understand anything, ask the person in charge of the study.
Title of Study: Characteristics and correlates of hot flashes in men with prostate cancer
Principal Investigator: Paul B. Jacobsen, Ph.D.
Study Location(s): H. Lee Moffitt Cancer Center
You are being asked to participate because you have been diagnosed with prostate cancer
and are being treated with hormonal therapy.
General Information about the Research Study
The purpose of this research study is to determine the prevalence and severity of hot
flashes experienced by men being treated with hormonal therapy. We would also like to
understand the impact these hot flashes may have on various aspects of your quality of
life.
Plan of Study
You will be asked to complete a packet of questionnaires prior to starting hormonal
therapy. Two weeks after you begin treatment, you will be asked to respond to some
questions regarding the prevalence and severity of the hot flashes you may be
experiencing. One month after you have started treatment, you will be asked to complete
a second packet of questionnaires, similar in content to the first packet. The second two
assessments may be completed in clinic or on the telephone.
Payment for Participation
You will not be paid for your participation in this study.
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Benefits of Being a Part of this Research Study
By taking part in this study, you will increase our knowledge regarding the experience of
hot flashes in men with prostate cancer.
Risks of Being a Part of this Research Study
There are no unpleasant or harmful side effects from participating in this study.
Confidentiality of Your Records
Your privacy and research records will be kept confidential to the extent of the law.
Authorized research personnel, employees of the Department of Health and Human
Services, and the USF Institutional Review Board may inspect the records from this
research project.
The results of this study may be published. However, the data obtained from you will be
combined with data from others in the publication. The published results will not include
your name or any other information that would personally identify you in any way.
Your name will not appear on any research form except for this informed consent form
and a master list, which will be maintained in a locked research file.
Volunteering to Be Part of this Research Study
Your decision to participate in this research study is completely voluntary. You are free
to participate in this research study or to withdraw at any time. There will be no penalty
or loss of benefits you are entitled to receive, if you stop taking part in the study. Your
medical care will not be affected.
Questions and Contacts
• If you have any questions about this research study, contact Erin Winters, M.A. at
1-800-456-3434 x 6187
• If you have questions about your rights as a person who is taking part in a
research study, you may contact the Division of Research Compliance of the
University of South Florida at (813) 974-5638.
Consent to Take Part in This Research Study
By signing this form I agree that:
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• I have fully read or have had read and explained to me this informed consent form
describing this research project.
• I have had the opportunity to question one of the persons in charge of this
research and have received satisfactory answers.
• I understand that I am being asked to participate in research. I understand the
risks and benefits, and I freely give my consent to participate in the research
project outlined in this form, under the conditions indicated in it.
• I have been given a signed copy of this informed consent form, which is mine to
keep.
___________________ _________________ _______________
Signature of Participant Printed Name of Participant Date
Investigator Statement
I have carefully explained to the subject the nature of the above research study. I hereby
certify that to the best of my knowledge the subject signing this consent form understands
the nature, demands, risks, and benefits involved in participating in this study.
___________________ ___________________ _______________
Signature of Investigator Printed Name of Investigator Date
Or authorized research
investigator designated by
the Principal Investigator
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Informed Consent for an Adult
University of South Florida, the IRB of record for the James A. Haley VA Hospital
Information for people who are being asked to take part in a research study
IRB Study #_103119___
Researchers at the James A. Haley VA Hospital study many topics. We want to learn
more about how hormonal therapy for prostate cancer affects our patients. To do this, we
need the help of people who agree to take part in a research study.
Person in charge of study: Raoul Salup, M.D.
Study staff who can act on behalf of the person in charge: Erin Winters, M.A., Sean
Ransom, M.A., Babu Zachariah, M.D., Joyce Shaw, Paul Jacobsen, Ph.D.
Where the study will be done: James A. Haley Veterans Hospital
Who is paying for it: Not applicable
Should you take part in this study?
This form tells you about this research study. You can decide if you want to take part in
it. You do not have to take part. Reading this form can help you decide.
Before you decide:
Read this form.
• Talk about this study with the person in charge of the study or the person explaining
the study. You can have someone with you when you talk about the study.
• Find out what the study is about.
You can ask questions:
• You may have questions this form does not answer. If you do, ask the person in
charge of the study or study staff as you go along.
• You dont have to guess at things you dont understand. Ask the people doing the
study to explain things in a way you can understand.
After you read this form, you can:
• Take your time to think about it.
• Have a friend or family member read it.
• Talk it over with someone you trust.
Its up to you. If you choose to be in the study, then you can sign the form. If you do not
want to take part in this study, do not sign the form.
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Why is this research being done?
The purpose of this study is to find out how the hot flashes associated with hormonal
therapy affect the mood, energy level, sleep quality, sexual functioning, and daily
activities of patients with prostate cancer.
Why are you being asked to take part?
We are asking you to take part in this study because you are scheduled to undergo
hormonal therapy for treatment of prostate cancer. We are interested in understanding
how the side effects associated with this form of treatment impact various aspects of your
quality of life.
How long will you be asked to stay in the study?
You will be asked to spend about three months in this study. This consists of the period
of time between the initial administration of hormonal therapy and your first clinical
follow-up visit. You will be assessed prior to beginning hormonal therapy and again six
weeks and three months after treatment has started.
How often will you need to come for study visits?
A study visit is one you have with the person in charge of the study or study staff. You
will need to come for 2 study visits in all.
You will be asked to fill out a packet of questionnaires that will take 25-30 minutes to
complete. You can either finish the questionnaires while you are at the VA, or you may
take them home with you and return them by mail. Approximately six weeks after this
initial assessment, you will be contacted at home by telephone and will be asked to report
on prevalence and severity of the hot flashes you may be experiencing.
Most study visits will take about 30 minutes. Some may be longer.
At each visit, the person in charge of the study or staff will:
• Provide you with a packet of questionnaires. These questionnaires will assess basic
demographic information (age, gender, marital status, etc), disease and treatment
variables, hot flashes, hot flash interference, fatigue, sleep quality, psychological
distress, masculine self-image, coping strategies, sexual functioning, treatment-
related side effects, and cognitive functioning.
• In between the 2 study visits, a member of the research team will contact you at
home. At this point, you will be asked to respond to questions regarding any hot
flashes you may be experiencing, and how they are impacting your daily activities.
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How many other people will take part?
About 65 people will take part in this study at James A. Haley VA Hospital. People will
also take part at other study sites. A total of about 89 people will take part.
What other choices do you have if you decide not to take part?
If you decide not to take part in this study, that is okay. Your treatment will not be
affected if you chose not to participate.
How do you get started?
If you decide to take part in this study, you will need to sign this consent form. You will
fill out the first questionnaire packet before you are started on hormonal therapy.
What will happen during this study?
During the study, you will be asked to respond to a number of questions regarding hot
flashes, your mood, sleep, physical functioning, and sexual functioning. You will fill out
a questionnaire packet at the beginning of the study and the same packet again at the end
of the study. These questionnaires will require approximately 25 to 30 minutes to
complete. Six weeks after the start of your treatment, you will be contacted by telephone
to respond to a few of these same questions. This telephone call will take approximately
5-10 minutes. The medical treatment you receive will be the same whether or not you
chose to participate.
Here is what you will need to do during this study
Study participation requires completing two questionnaire packets and one brief
telephone interview.
Will you be paid for taking part in this study?
We will not pay you for the time you volunteer in this study.
What will it cost you to take part in this study?
It will not cost you anything to take part in the study.
What are the potential benefits if you take part in this study?
Although there are no direct benefits to you, by taking part in this study, you will increase
our knowledge regarding the experience of hot flashes in men with prostate cancer. What
we learn may help others with this stage of prostate cancer.
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What are the risks if you take part in this study?
Although we do not expect there to be any unpleasant or harmful side effects from
participating in this study, you may experience some psychological discomfort from
filling out some of the questionnaires.
What will we do to keep your study records from being seen by others?
Federal law requires us to keep your study records private. Participants will be assigned a
three-digit code number that will be used on all study materials. Informed consent
documents will be maintained in a locked research file in a secure area of the Moffitt
Research Center building. Completed questionnaires will be stored in a different file,
separated from any identifying information. Research data will be entered into a data
analysis program. This data will be entered using the three-digit code number; no
identifying information will be stored digitally. The privacy and research records of the
participants will be kept confidential to the extent of the law.
However, certain people may need to see your study records. By law, anyone who looks
at your records must keep them confidential. The only people who will be allowed to see
these records are:
• The study staff.
• People who make sure that we are doing the study in the right way. They also make
sure that we protect your rights and safety:
o The USF Institutional Review Board (IRB) and its staff
o The Department of Veterans Affairs (VA)
o The United States Department of Health and Human Services (DHHS)
We may publish what we find out from this study. If we do, we will not use your name
or anything else that would let people know who you are.
What happens if you decide not to take part in this study?
You should only take part in this study if you want to take part.
If you decide not to take part:
• You wont be in trouble or lose any rights you normally have.
• You will still get the same services you would normally have.
• You can still get your regular medical treatment.
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What if you join the study and then later decide you want to stop?
If you decide you want to stop taking part in the study, tell the study staff as soon as you
can.
• We will tell you how to stop safely. We will tell you if there are any dangers if you
stop suddenly.
• If you decide to stop, you can go on getting your regular medical treatment.
Are there reasons we might take you out of the study later on?
Even if you want to stay in the study, there may be reasons we will need to take you out
of it. You may be taken out of this study:
• If we find out it is not safe for you to stay in the study. For example, your health may
get worse.
• If you are not coming for your study visits when scheduled.
You can get the answers to your questions.
If you have any questions about this study, call Dr. Raoul Salup at (813) 972-2000 x7579.
If you have questions about your rights as a person who is taking part in a study, call USF
Research Compliance at (813) 974-5638.
You may also contact the James A. Haley VA Hospital Research Compliance Officer at
(813) 972-2000 ext. 7872.
Signatures for Consent to Take Part in this Research Study
Its up to you. You can decide if you want to take part in this study.
I freely give my consent to take part in this study. I understand that this is research.
I have received a copy of this consent form.
___________________________________________ ___________
Signature of Person Taking Part in Study Date
___________________________________________
Printed Name of Person Taking Part in Study
___________________________________________ ___________
Signature of Witness Date
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___________________________________________
Printed Name of Witness
Statement of Person Obtaining Informed Consent
I have carefully explained to the person taking part in the study what he can expect.
The person who is giving consent to take part in this study
• Understands the language that is used.
• Reads well enough to understand this form. Or is able to hear and understand when
the form is read to him or her.
• Does not have any problems that could make it hard to understand what it means to
take part in this study.
• Is not taking drugs that make it hard to understand what is being explained.
To the best of my knowledge, when this person signs this form, he or she understands:
• What the study is about.
• What needs to be done.
• What the potential benefits might be.
• What the known risks might be.
• That taking part in the study is voluntary.
__________________________________________ ___________
Signature of person obtaining consent Date
___________________________________________
Printed name of person obtaining consent
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Characteristics and correlates of hot flashes in men with prostate cancer
H. Lee Moffitt Cancer Center and Research Institute
at the University of South Florida
RESEARCH AUTHORIZATION
We understand that information about you and your health is personal, and we are
committed to protecting the privacy of that information. Because of this commitment, we
must obtain your written authorization before we may use or disclose your protected
health information for the research purposes described below. This form provides that
authorization and helps us make sure that you are properly informed of how this
information will be used or disclosed.
Research undertaken at the H. Lee Moffitt Cancer Center and Research Institute, Inc. or
at any of its subsidiaries is undertaken jointly with the University of South Florida or
other persons or entities under an organized health care arrangement. All persons or
entities participating in such an organized healthcare arrangement are collectively
referred to as the "Moffitt Cancer Center" in this form.
By signing this document you are permitting the Moffitt Cancer Center to use personal
health information collected about you for research purposes internally within its
organized health care arrangements. You are also allowing the Moffitt Cancer Center to
disclose that personal health information to outside organizations or individuals that
participate in this research study. Please read the information below carefully before
signing this form.
USE AND DISCLOSURE COVERED BY THIS AUTHORIZATION
A representative of the Moffitt Cancer Center must answer these questions completely
before providing this authorization form to you. DO NOT SIGN A BLANK FORM. You
or your personal representative should read the descriptions below before signing this
form.
Who will disclose, receive, and/or use the information? The workforce of the Moffitt
Cancer Center is permitted by law to use and disclose your health information for
treatment, payment and health care operations purposes. By signing below, you
authorize the Moffitt Cancer Center to receive and obtain tests, results and your other
personal health and related information arising from services or treatment provided to
you by other health care providers in connection with this study. In addition to any uses
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or disclosures made for treatment, payment and health care operations purposes, the
following person(s), class(es) of persons, and/or organization(s) will be allowed to
disclose, use, and receive the information for the research purposes set forth in this form,
but they may only use and disclose the information to the other parties on this list, to you
or your personal representative, or as permitted by law.
Every research site for this study, including the Moffitt Cancer Center, and including
each sites research staff and medical staff
Every health care provider and other member of the Moffitt Cancer Center workforce
who provides services to you in connection with this study
3. Any laboratories and other individuals and organizations that use your health
information in connection with this study in accordance with the studys protocol
4. Any sponsor of the study, including the following research sponsors: None
5. The United States Food and Drug Administration, Department of Health and Human
Services (DHHS) and any other federal, state or local governmental agency that
regulates the research study
6. The designated research Protocol Review and Monitoring Committees and related
staff of the Moffitt Cancer Center
7. The National Cancer Institute in evaluating the ongoing research of the Moffitt
Cancer Center as a Comprehensive Cancer Center
8. The members and staff of any Institutional Review Board that has oversight
responsibility for this study
9. The members and staff of the Moffitt Cancer Centers affiliated Privacy Board
10. Members of the study team, including the following Principal Investigator, co-
investigators, sub-investigators and others listed on your research study Informed
Consent
11. Study Coordinators, Research Nurses and Data Managers involved in the research
12. Members of the Moffitt Cancer Centers Clinical Trials Office/Clinical Research
Operations
13. Contract Research Organization
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14. Data Safety Monitoring Board and Staff
Additionally, the following person(s), classes of person(s), and/or organization(s) (as
described below):
The entities and persons listed above may employ or pay various consultants and
companies to help them understand, analyze and conduct this study. All of these people
may not be known
now, but if you would like to have more specific information about this at any time
during the study, you may ask the Principal Investigator and your questions will be
answered.
The Moffitt Cancer Center cannot guarantee the privacy of your information, or block
further use or distribution, after the information has left the Moffitt Cancer Center. The
sponsor of this study may further disclose your information. If disclosed by the sponsor
or any other person or entity, the information may no longer be covered by the federal
privacy regulations.
What information will be used or disclosed? By signing below, you authorize the use
and disclosure of your entire research record and any medical or other records held by the
Moffitt Cancer Center, including, but not limited to, HIV/AIDS, mental health, substance
abuse or genetic information, except for information that you expressly exclude below.
The purpose for the uses and disclosures you are authorizing is to conduct the research
project explained to you during the informed consent process and to ensure that the
information relating to that research is available to all parties who may need it for
research purposes.
! Exclude the information expressly listed below (if blank, then no information
excluded):
SPECIFIC UNDERSTANDINGS
By signing this research authorization form, you authorize the use and/or disclosure of
your protected health information described above. Your information may also be used
as necessary for your research-related treatment, to collect payment for your research-
related treatment (when applicable), and to run the business operations of the Moffitt
Cancer Center.
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This information may be redisclosed if the recipient(s) described on this form is not
required by law to protect the privacy of the information.
You have a right to refuse to sign this authorization. While your health care outside the
study, the payment for your health care, and your health care benefits will not be affected
if you do not sign this form, you will not be able to participate in the research described
in this authorization and will not receive treatment as a study participant if you do not
sign this form.
If you sign this authorization, you will have the right to revoke it at any time, except to
the extent that the Moffitt Cancer Center has already taken action based upon your
authorization or needs the information to complete analysis and reports of data for this
research. Your revocation will apply prospectively only. All data collected prior to your
decision to withdraw your authorization to use the data for research purposes - including
documentation of your decision to withdraw - may still be used by the Principal
Investigator and cannot be revoked. If medically necessary, the Principal Investigator or
study staff may follow-up with you. If you have decided to withdraw your authorization
to use the data for research purposes this follow-up information cannot be used or
disclosed for research unless required by law.
This authorization will never expire unless and until you expressly revoke it in writing.
To revoke this authorization, please write to Paul Jacobsen, Ph.D. at the Moffitt Cancer
Center 12902 Magnolia Dr. Tampa, FL 33612.
By signing below, you acknowledge your receipt of a copy of this form.
SIGNATURE
I have read this form and all of my questions about this form have been answered. By
signing below, I acknowledge that I have read and accept all of the above.
_________________________________________
Signature of Subject or Personal Representative
_________________________________________
Print Name of Subject or Personal Representative
_________________________________________
Date
_________________________________________
Description of Personal Representatives Authority
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CONTACT INFORMATION
The contact information of the subject or personal representative who signed this form
should be filled in below.
Address:
______________________________
______________________________
______________________________
______________________________
Telephone:
___________________ (daytime)
___________________ (evening)
Email Address (optional):
____________________________
THE SUBJECT OR HIS OR HER PERSONAL REPRESENTATIVE MUST BE
PROVIDED WITH A COPY OF THIS FORM AFTER IT HAS BEEN SIGNED.
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Department of Veterans Affairs
Authorization for Release of Protected Health Information for Research Purposes
Title of Study: Characteristics and Correlates of Hot Flashes in Men with Prostate
Cancer
You have been asked to be part of a research study under the direction of Raoul Salup,
M.D. and his research team. The purpose of this study is to find out how the hot flashes
associated with hormonal therapy affect the mood, energy level, sleep quality, sexual
functioning, and daily activities of patients with prostate cancer.
By signing this document, you will authorize the Veterans Health Administration (VHA)
to provide Raoul Salup, M.D. and his research team permission to use and disclose the
following information about you:
The information that will be released includes information regarding the following
conditions:
Demographic information
Medical treatment history
The research team may also need to disclose the information to others as part of the study
process. The others may include the institutional review board.
If you do not sign this authorization, you will not participate in the study.
This authorization to use your information will expire at the end of the research study.
You can revoke this authorization, in writing, at any time. To revoke your authorization,
you must write to the Release of Information Office at this facility or you can ask a
member of the research team to give you a form to revoke the authorization. Your
request will be valid when the Release of Information Office receives it. If you revoke
this authorization, you will not be able to continue to participate in the study. This will
not affect your right as a VHA patient to treatment or benefits outside the study.
If you revoke this authorization, Raoul Salup, M.D. and his research team can continue to
use information about you that was collected before receipt of the revocation. The
research team will not collect information about you after you revoke the authorization.
The VHA complies with the requirements of the Health Insurance Portability and
Accountability Act of 1996 and its privacy regulations and all other applicable laws that
protect your privacy. We will protect your information according to these laws. Despite
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these protection, there is a possibility that your information could be used or disclosed in
a way that it will no longer be protected. Our Notice of Privacy Practices (a separate
document) provides more information on how we protect your information. If you do not
have a copy of the Notice, the research team will provide one to you.
I have read this authorization form and have been given the opportunity to ask questions.
If I have questions later, I understand I can contact Raoul Salup, M.D. I will be given a
signed copy of this authorization form for my records. I authorize the use of my
identifiable information as described in this form.
__________________________________
Signature of Participant or Person Authorized
To Sign for Participant (Attach authority to sign,
e.g., Power of Attorney)
The execution of this form does not authorize the release of information other than that specifically described. The
information requested on this form is solicited under Title 38, U.S.C. The form authorizes release of information that
you specify in accordance with the Health Insurance Portability and Accountability Act, 45 CFR Parts 160 and 164, 5
U.S.C. 552a, and 38 U.S.C. 5701 and 7332. Your disclosure of information requested on this form is voluntary.
However if the information, including Social Security Number (SSN) (the SSN will be used to locate records for
release) is not furnished completely and accurately, Department of Veterans Affairs will be unable to comply with the
request.
The Paperwork Reduction Act of 1995 requires us to notify you that this information collection is in accordance with
the clearance requirements of section 3507 of the Act. We may not conduct or sponsor, and you are not required to
respond to, a collection of information unless it displays a valid OMB number. We expect that the time expended by all
individuals completing this form will average 2 minutes. This includes the time to read the instructions, gather the
necessary facts and fill out the form. The purpose of this form is to specifically outline the circumstances under which
we may disclose data.
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1. Today's date: ⁪⁪/⁪⁪ /⁪⁪ (month/day/year)
2. Birth date:⁪⁪ /⁪⁪/⁪⁪ (month/day/year)
3. Height:⁪ (ft)⁪⁪ (in)
4. Weight:⁪⁪⁪ (pounds)
5. Which of the following best describes your ethnic background?
⁪ 1 Spanish/Hispanic/Latino
⁪ 2 Not Spanish/Hispanic/Latino
6. What is your race? (check one box)
⁪ 1 White/Caucasian ⁪ 4 American Indian/Alaska Native
⁪ 2 Black/African American ⁪ 5 Other:_____________________
⁪ 3 Asian/Pacific Islander
7. Marital status (check one box):
⁪ 1 Never married ⁪ 4 Divorced
⁪ 2 Currently married ⁪ 5 Widowed
⁪ 3 Separated
8. Current living arrangement (check one box):
⁮ 1 Live alone ⁮ 5 Live with roommate who
⁪ 2 Live with spouse/partner is not partner
⁪ 3 Live with spouse/partner and children ⁪ 6 Live with parents
⁪ 4 Live with children (no spouse/partner) ⁪ 7 Other (specify)__________
9. How long in current living arrangement (check one box):
⁪ 1 Less than 1 month ⁪ 4 Two to 5 years
⁪ 2 One to 6 months ⁪ 5 More than 5 years
⁪ 3 Seven months to 2 years
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10. Level of school completed (check one box):
⁮ 1 Less than 7th grade ⁮ 5 Partial college or specialized training
⁮ 2 Junior High School ⁮ 6 College or university graduate
(7th, 8th, & 9th grade) ⁮ 7 Graduate professional training
⁮ 3 Partial high school (graduate degree)
(10th or 11th grade)
⁮ 4 High School graduate
11. Current employment situation (check all that apply):
⁮ 1 Full time at job
⁮ 2 Part time at job
⁮ 3 On leave with pay
⁮ 4 On leave without pay
⁮ 5 Disabled
⁮ 6 Seeking work
⁮ 7 Retired
⁮ 8 Homemaker
⁮ 9 Student
12. Which category best describes your usual occupation? If you are not currently
employed, which category best describes your LAST job? (check one number):
⁮ 1. Professional (e.g. teachers/professors, nurses, lawyers, physicians, &
engineers)
⁮ 2. Manager/Administrator (e.g., sales managers)
⁮ 3. Clerical (e.g., secretaries, clerks or mail carriers)
⁮ 4. Sales (e.g., sales persons, agents & brokers)
⁮ 5. Service (e.g., police, cooks, waitress, or hairdressers)
⁮ 6. Skilled Crafts, Repairer (e.g., carpenters)
⁮ 7. Equipment or Vehicle Operator (e.g., truck drivers)
⁮ 8. Laborer (e.g., maintenance factory workers)
⁮ 9. Farmer (e.g., owners, managers, operators or tenants)
⁮ 10. Member of the military
⁮ 11. Homemaker (with no job outside the home)
⁮ 12. Other (please describe)________________________________________
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13. Which category best describes your spouses usual occupation? If your spouse is
not currently employed, which category best describes his/her LAST job? (check
one number)
⁮ 1. Professional (e.g., teachers/professors, nurses, lawyers, physicians, &
engineers)
⁮ 2. Manager/Administrator (e.g., sales managers)
⁮ 3. Clerical (e.g., secretaries, clerks or mail carriers)
⁮ 4. Sales (e.g., sales persons, agents & brokers)
⁮ 5. Service (e.g., police, cooks, waitress, or hairdressers)
⁮ 6. Skilled Crafts, Repairer (e.g., carpenters)
⁮ 7. Equipment or Vehicle Operator (e.g., truck drivers)
⁮ 8. Laborer (e.g., maintenance factory workers)
⁮ 9. Farmer (e.g., owners, managers, operators or tenants)
⁮ 10. Member of the military
⁮ 11. Homemaker (with no job outside the home)
⁮ 12. Other (please describe)____________________________________
14. What is your approximate annual gross income? (check one number)
(Remember all information you provide will remain completely confidential)
⁮ 1 Less than $ 10,000 ⁮ 4 $40,000 - $59,999
⁮ 2 $10,000 - $19,999 ⁮ 5 $60,000 - $100,000
⁮ 3 $20,000 - $ 39,999 ⁮ 6 Greater than $100,000
15. Approximate annual gross income for your household: (check one number)
(Remember all information you provide will remain completely confidential)
⁮ 1 Less than $ 10,000 ⁮ 4 $40,000 - $59,999
⁮ 2 $10,000 - $19,999 ⁮ 5 $60,000 - $100,000
⁮ 3 $20,000 - $ 39,999 ⁮ 6 Greater than $100,000
101
Appendix E: (Continued)
22. Which of the following best describes how you presently function?
⁮ 1 I am able to carry on normal activity or do work and I have no physical
complaints or problems.
⁮ 2 I am able to carry on normal activity or do work even with minor physical
complaints.
⁮ 3 I am able to carry on normal activity or do work but it takes effort because
of physical problems.
⁮ 4 I am unable to carry on normal activity but I care for myself.
⁮ 5 I am unable to carry on normal activity and I require occasional help from
others, but I am able to care for most of my personal needs.
⁮ 6 I require considerable help from others and I require frequent medical
care.
⁮ 7 I am disabled and I require special care and help.
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Appendix F: Hot Flash Questionnaire
Please respond to the following questions in regards to the past two weeks. A hot flash is
a short-lived episode of flushing, sweating, and a sensation of heat. It is often
accompanied by heart palpitations and a feeling of anxiety and may sometimes be
followed by chills.
1. Have you experienced hot flashes in the past two weeks?
⁮ yes
⁮ no (please go on to next page)
2. Approximately how many hot flashes have you experienced over the past two
weeks? ______
3. Please rate the severity of your hot flashes on average over the past two weeks.
⁮ Mild
⁮ Moderate
⁮ Severe
⁮ Very severe
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Appendix G: Hot Flash-Related Daily Interference Scale
Please check one box to describe how much DURING THE PAST WEEK hot flashes
have INTERFERED with each aspect of your life. Higher numbers indicate more
interference with your life. If you are not experiencing hot flashes or if hot flashes do not
interfere with these aspects of your life, please mark zero to the right of each question.
Do not Completely
interfere interfere
0 1 2 3 4 5 6 7 8 9 10
1. Work (outside the home and
housework) ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
2. Social activities (time spent
with family, friends,etc.) ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
3. Leisure activities (time spent
relaxing, doing hobbies, etc.) ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
4. Sleep ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
5. Mood ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
6. Concentration ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
7. Relations with others ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
8. Sexuality ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
9. Enjoyment of life ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
10. Overall quality of life ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
Appendix H: Fatigue Symptom Inventory
For each of the following, check one box next to the number that best indicates how that
item applies to you.
1. Rate your level of fatigue on the day you felt most fatigued during the past week:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
Not at all As fatigued
fatigued as I could be
2. Rate your level of fatigue on the day you felt least fatigued during the past week:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
Not at all As fatigued
fatigued as I could be
3. Rate your level of fatigue on the average during the past week:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
Not at all As fatigued
fatigue as I could be
4. Rate your level of fatigue right now:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
Not at all As fatigued
fatigued as I could be
5. Rate how much, in the past week, fatigue interfered with your general level of
activity:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
Not at all As fatigued
fatigued as I could be
6. Rate how much, in the past week, fatigue interfered with your ability to bathe and
dress yourself:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
No Extreme
interference interference
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7. Rate how much, in the past week, fatigue interfered with your normal work activity
(includes both work outside the home and housework):
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
No Extreme
interference interference
8. Rate how much, in the past week, fatigue interfered with your ability to concentrate:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
No Extreme
interference interference
9. Rate how much, in the past week, fatigue interfered with your relations with other
people:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
No Extreme
interference interference
10. Rate how much, in the past week, fatigue interfered with your enjoyment of life:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
No Extreme
interference interference
11. Rate how much, in the past week, fatigue interfered with your mood:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
No Extreme
interference interference
12. Indicate how many days, in the past week, you felt fatigued for any part of the day:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7
Days Days
13. Rate how much of the day, on average, you felt fatigued in the past week:
⁮0 ⁮1 ⁮2 ⁮3 ⁮4 ⁮5 ⁮6 ⁮7 ⁮8 ⁮9 ⁮10
None of The entire
the day day
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14. Indicate which of the following best describes the daily pattern of your fatigue
in the past week:
⁮ 0 ⁮ 1 ⁮ 2 ⁮ 3 ⁮ 4
Not at all Worse in Worse in Worse in No consistent daily
fatigued the morning the afternoon the evening pattern of fatigue
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Appendix I: Pittsburgh Sleep Quality Index
The following questions relate to your usual sleep habits during the past week only. Your
answers should indicate the most accurate reply for the majority of days and nights in the
past week. Please answer all questions.
1. During the past week, when have you usually gone to bed at night?
USUAL BED TIME ____________
2. During the past week, how long (in minutes) has it usually taken you to fall asleep
each night?
NUMBER OF MINUTES ______________
3. During the past week, when have you usually gotten up in the morning?
USUAL GETTING UP TIME ________________
4. During the past week, how many hours of actual sleep did you get a night? (This
may be different than the number of hours you spend in bed.)
HOURS OF SLEEP PER NIGHT _______________
For each of the remaining questions, check the one best response. Please answer all
questions.
5. During the past week, how often have you had trouble sleeping because you cannot
get to sleep within 30 minutes?
Not A few Several Every night or
at all _____ (1-2) times _____ (3-5) times _____ almost every night _____
6. During the past week, how would you rate your sleep quality overall?
Very good _____ Fairly good ______ Fairly bad _______ Very bad _______
7. During the past week, how often have you taken medicine (prescribed or over the
counter) to help you sleep?
Not A few Several Every night or
at all _____ (1-2) times _____ (3-5) times _____ almost every night _____
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Appendix J: Center for Epidemiological Studies-Depression Scale
For each statement below, make an X in the box which best describes how often you
felt or behaved this way-- DURING THE PAST WEEK, INCLUDING TODAY.
DURING THE PAST WEEK: None of
the time
A little of
the time
A moderate
amount of
the time
All of
the
time
1. I was bothered by things that usually
didnt bother me. ⁮ ⁮ ⁮ ⁮
2. I didnt feel like eating; my appetite
was poor. ⁮ ⁮ ⁮ ⁮
3. I felt that I could not shake off the
blues even with help from family or
friends ⁮ ⁮ ⁮ ⁮
4. I felt that I was just as good as other
people. ⁮ ⁮ ⁮ ⁮
5. I had trouble keeping my mind on
what I was doing. ⁮ ⁮ ⁮ ⁮
6. I felt depressed... ⁮ ⁮ ⁮ ⁮
7. I felt that everything I did was an
effort. ⁮ ⁮ ⁮ ⁮
8. I felt hopeful about the future ⁮ ⁮ ⁮ ⁮
9. I thought my life had been a failure... ⁮ ⁮ ⁮ ⁮
10. I felt fearful.. ⁮ ⁮ ⁮ ⁮
11. My sleep was restless.. ⁮ ⁮ ⁮ ⁮
12. I was happy. .. ⁮ ⁮ ⁮ ⁮
13. I talked less than usual. ... ⁮ ⁮ ⁮ ⁮
14. I felt lonely. . ⁮ ⁮ ⁮ ⁮
15. People were unfriendly ⁮ ⁮ ⁮ ⁮
109
Appendix J: (Continued)
None of
the time
A little of
the time
A moderate
amount of
the time
All of
the
time
16. I enjoyed life ⁮ ⁮ ⁮ ⁮
17. I had crying spells. .. ⁮ ⁮ ⁮ ⁮
18. I felt sad. .. ⁮ ⁮ ⁮ ⁮
19. I felt that people disliked me. .. ⁮ ⁮ ⁮ ⁮
20. I could not get going. ⁮ ⁮ ⁮ ⁮
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Appendix K: Impact of Events Scale
Below is a list of comments made by people about stressful events. For each item, put an
X in the box that indicates how frequently these comments were true for you DURING
THE PAST WEEK INCLUDING TODAY ABOUT YOUR CANCER AND ITS
TREATMENT. If they did not occur during that time, please mark the "not at all"
column.
Not at all Rarely Sometimes Often
1. Thought about it when I didn't mean to...    
2. I avoided letting myself get upset when
I thought about it or was reminded of it..    
3. I tried to remove it from memory    
4. I had trouble falling asleep or staying
asleep, because of pictures or thoughts
about it that came into my mind    
5. I had waves of strong feelings about it..    
6. I had dreams about it.    
7. I stayed away from reminders of it    
8. I felt as if it was not real    
9. I tried not to talk about it...    
10. Pictures about it popped into my mind.    
11. Other things kept making me think
about it.    
12. I was aware that I had a lot of feelings
about it, but I didn't deal with them.    
13. I tried not to think about it    
11. Any reminder brought back feelings
about it.    
15. My feelings about it were kind of numb..    
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Not at all Rarely Sometimes Often
16. I avoided talking about cancer,
even if it was on my mind.    
17. Thoughts about cancer popped into
my mind    
18. I tried to avoid even saying the
word cancer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Appendix L: Bem Sex Role Inventory  Short Form
Listed below, you will find a number of personality characteristics. Use those
characteristics to describe yourself. Check the box corresponding to how true each of
these characteristics is. Please do not leave any characteristic unmarked.
Never
or
almost
never
true
Usual-
ly
not
true
Some-
times,
but
infrequ-
ently
true
Occasi
onally
true
Often
true
Usually
true
Always
or
almost
always
true
1. Defend my
own
beliefs
⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
2. Affectionate ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
3. Conscientious ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
4. Independent ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
5. Sympathetic ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
6. Moody ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
7. Assertive ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
8. Sensitive to
needs of
others.. ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
9. Reliable ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
10. Strong
personality ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
11. Under-
standing
12. Jealous. ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
13. Forceful ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
14. Compas-
sionate.. ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
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Never
or
almost
never
true
Usual-
ly
not
true
Some-
times,
but
infreq-
uently
true
Occasi
onally
true
Often
true
Usually
true
Always
or
almost
always
true
15. Truthful ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
16. Have
leadership
abilities. ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
17. Eager to
sooth hurt
feelings. ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
18. Secretive ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
19. Willing to
take risks ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
20. Warm ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
21. Adaptable ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
22. Dominant ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
23. Tender ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
24. Conceited ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
25. Willing to
take a stand ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
26. Love child-
ren ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
27. Tactful ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
28. Aggressive ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
29. Gentle ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
30. Conventional ⁮ ⁮ ⁮ ⁮ ⁮ ⁮ ⁮
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Appendix M: Hot Flash Catastrophizing Scale (Baseline)
Instructions: The following statements describe different thoughts people have when
they experience hot flashes. A hot flash is a short-lived episode of flushing, sweating,
and a sensation of heat. It is often accompanied by heart palpitations and a feeling
of anxiety and may sometimes be followed by chills. For each statement, please check
the box that indicates how you imagine you might respond if you were to experience hot
flashes. Mark only one response for each item and try to answer every item.
One
Some half Most All
of the of the of the of the
Never time time time time
true true true true true
1. I would feel like I just wanted
to get up and run away. . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
2. I would imagine the hot flashes
becoming even more intense and
exhausting. . . . . . . . . . .  ⁮ ⁮ ⁮ ⁮ ⁮
3. I would begin thinking of all the possible
things that could go wrong in
association with the hot flashes. . . . . . .. ⁮ ⁮ ⁮ ⁮ ⁮
4. I would tell myself that I dont think
I could bear the hot flashes. . . ⁮ ⁮ ⁮ ⁮ ⁮
5. I would find myself worrying about
possibly dying. . . . . . . . . . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
6. I would expect the worst. . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
7. I would think that my hot flashes
were pretty awful. . . . . . . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
8. I would find myself concentrating
on how terrible the hot flashes
actually felt. .. ⁮ ⁮ ⁮ ⁮ ⁮
9. I would find it virtually impossible
to keep my mind off my hot flashes . . .. ⁮ ⁮ ⁮ ⁮ ⁮
10. I would begin to worry that something
might be seriously wrong with me. . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
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Appendix N: Hot Flash Catastrophizing Scale (3 Month Follow-Up)
Instructions: The following statements describe different thoughts people have when
they experience hot flashes. If you have experienced hot flashes in the past two weeks,
please respond to the items below. If you have NOT experienced hot flashes, you
may go on to the next page. For each statement, please check the box that indicates how
you have felt in the past two weeks. Mark only one response for each item and try to
answer every item.
One
Some half Most All
of the of the of the of the
Never time time time time
true true true true true
1. I felt like I just wanted
to get up and run away. . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
2. I imagine the hot flashes
becoming even more intense and
exhausting. . . . . . . . . . .  ⁮ ⁮ ⁮ ⁮ ⁮
3. I think of all the possible
things that could go wrong in
association with the hot flashes. . . . . . .. ⁮ ⁮ ⁮ ⁮ ⁮
4. I tell myself that I cant
bear the hot flashes. . . ⁮ ⁮ ⁮ ⁮ ⁮
5. I find myself worrying about
possibly dying. . . . . . . . . . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
6. I expect the worst. . . . . . . . . . . .  ⁮ ⁮ ⁮ ⁮ ⁮
7. I think that my hot flashes
are pretty awful. . . . . . . . . . . . . . . . . . ⁮ ⁮ ⁮ ⁮ ⁮
8. I find myself concentrating
on how terrible the hot flashes
actually feel. .. ⁮ ⁮ ⁮ ⁮ ⁮
9. I find it virtually impossible
to keep my mind off my hot flashes . . .. ⁮ ⁮ ⁮ ⁮ ⁮
10. I worry that something might
be seriously wrong with me. .  . . . . ⁮ ⁮ ⁮ ⁮ ⁮
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Appendix O: Expanded Prostate Cancer Index Composite
This questionnaire is designed to measure Quality of Life in patients with Prostate cancer.
To help us get the most accurate measurement, it is important that you answer all
questions honestly and completely.
This section is about your urinary habits. Please consider ONLY THE LAST 4 WEEKS.
1. Over the past 4 weeks, how often have you leaked urine? (Check only one box)
⁮ More than once a day
⁮ About once a day
⁮ More than once a week
⁮ About once a week
⁮ Rarely or never
2. Which of the following best describes your urinary control during the last 4
weeks? (Check one box)
⁮ No urinary control whatsoever
⁮ Frequent dribbling
⁮ Occasional dribbling
⁮ Total control
3. How many pads or adult diapers per day did you usually use to control leakage
during the last 4 weeks? (Check one box)
⁮ None
⁮ 1 pad per day
⁮ 2 pads per day
⁮ 3 or more pads per day
4. How big a problem, if any, has each of the following been for you during the last
4 weeks? (Check one box on each line)
No Very small Small Moderate Big
problem problem problem problem problem
a. Dripping or leaking
urine.. ⁮ ⁮ ⁮ ⁮ ⁮
b. Pain or burning on
urination ⁮ ⁮ ⁮ ⁮ ⁮
c. Bleeding with
urination ⁮ ⁮ ⁮ ⁮ ⁮
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No Very small Small Moderate Big
problem problem problem problem problem
d. Weak urine stream
Or incomplete emptying ⁮ ⁮ ⁮ ⁮ ⁮
e. Waking up to urinate ⁮ ⁮ ⁮ ⁮ ⁮
f. Need to urinate
frequently during the day... ⁮ ⁮ ⁮ ⁮ ⁮
5. Overall, how big a problem has your urinary function been for you during the last 4
weeks?
⁮ No problem
⁮ Very small problem
⁮ Small problem
⁮ Moderate problem
⁮ Big problem
________________________________________________________________________
This next section is about your bowel habits and abdominal pain. Please consider ONLY
THE LAST 4 WEEKS.
6. How big a problem, if any, has each of the following been for you? (check one box on
each line)
No Very small Small Moderate Big
problem problem problem problem problem
a. Urgency to have a
bowel movement.. ⁮ ⁮ ⁮ ⁮ ⁮
b. Increased frequency
of bowel movements ⁮ ⁮ ⁮ ⁮ ⁮
c. Watery bowel
movements.. ⁮ ⁮ ⁮ ⁮ ⁮
d. Losing control of your
stools. ⁮ ⁮ ⁮ ⁮ ⁮
e. Bloody stools. ⁮ ⁮ ⁮ ⁮ ⁮
f. Abdominal/pelvic/rectal
pain.. ⁮ ⁮ ⁮ ⁮ ⁮
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7. Overall, how big a problem have your bowel habits been for you during the last 4
weeks? (Check one box)
⁮ No problem
⁮ Very small problem
⁮ Small problem
⁮ Moderate problem
⁮ Big problem
________________________________________________________________________
This next section is about your current sexual function and sexual satisfaction. Many of
the questions are very personal, but they will help us understand the important issues that
you face everyday. Remember, THIS SURVEY INFORMATION IS COMPLETETLY
CONFIDENTIAL. Please answer honestly about THE LAST 4 WEEKS ONLY.
8. How would you rate each of the following during the last 4 weeks? (Check one box
on each line)
Very poor Very
to none Poor Fair Good good
a. Your level of sexual desire? ⁮ ⁮ ⁮ ⁮ ⁮
b. Your ability to have an erection ⁮ ⁮ ⁮ ⁮ ⁮
c. Your ability to reach orgasm (climax)? ⁮ ⁮ ⁮ ⁮ ⁮
9. How would you describe the usual QUALITY of your erections during the last 4
weeks? (Check one box)
⁮ None at all
⁮ Not firm enough for any sexual activity
⁮ Firm enough for masturbation and foreplay only
⁮ Firm enough for intercourse
10. How would you describe the FREQUENCY of your erections during the last 4
weeks? (Check one box)
⁮ I NEVER had an erection when I wanted one
⁮ I had an erection LESS THAN HALF the time I wanted one
⁮ I had an erection ABOUT HALF the time I wanted one
⁮ I had an erection MORE THAN HALF the time I wanted one
⁮ I had en erection WHENEVER I wanted one
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11. How often have you awakened in the morning or night with an erection during the
last 4 weeks?
⁮ Never
⁮ Less than once a week
⁮ About once a week
⁮ Several times a week
⁮ Daily
12. During the last 4 weeks, how often did you have any sexual activity?
⁮ Not at all
⁮ Less than once a week
⁮ About once a week
⁮ Several times a week
⁮ Daily
13. During the last 4 weeks, how often did you have sexual intercourse?
⁮ Not at all
⁮ Less than once a week
⁮ About once a week
⁮ Several times a week
⁮ Daily
14. Overall, how would you rate your ability to function sexually during the last 4
weeks? (Check one box)
⁮ Very poor
⁮ Poor
⁮ Fair
⁮ Good
⁮ Very good
15. How big a problem during the last 4 weeks, if any, has each of the following been
for you? (Check one box on each line)
No Very small Small Moderate Big
problem problem problem problem problem
a. Your level of
sexual desire.. ⁮ ⁮ ⁮ ⁮ ⁮
b. Your ability to have
an erection. ⁮ ⁮ ⁮ ⁮ ⁮
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No Very small Small Moderate Big
problem problem problem problem problem
c. Your ability to reach
orgasm.. ⁮ ⁮ ⁮ ⁮ ⁮
16. Overall, how big a problem has your sexual function or lack of sexual function been
for you during the last 4 weeks? (Check one box)
⁮ No problem
⁮ Very small problem
⁮ Small Problem
⁮ Moderate problem
⁮ Big problem
________________________________________________________________________
This next section is about your hormonal function. Please consider ONLY THE LAST 4
WEEKS.
17. Over the last 4 weeks, how often have you experienced hot flashes? (Check one box)
⁮ More than once a day
⁮ About once a day
⁮ More than once a week
⁮ About once a week
⁮ Rarely or never
18. How often have you had breast tenderness during the last 4 weeks? (Check one box)
⁮ More than once a day
⁮ About once a day
⁮ More than once a week
⁮ About once a week
⁮ Rarely or never
19. During the last 4 weeks, how often have you felt depressed? (Check one box)
⁮ More than once a day
⁮ About once a day
⁮ More than once a week
⁮ About once a week
⁮ Rarely or never
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20. During the last 4 weeks, how often have you felt a lack of energy? (Check one box)
⁮ More than once a day
⁮ About once a day
⁮ More than once a week
⁮ About once a week
⁮ Rarely or never
21. How much change in your weight have you experienced during the last 4 weeks, if
any? (Check one box)
⁮ Gained 10 pounds or more
⁮ Gained less than 10 pounds
⁮ No change in weight
⁮ Lost less than 10 pounds
⁮ Lost 10 pounds or more
22. How big a problem, during the last 4 weeks, if any, has each of the following been
for you? (Check one box on each line)
No Very small Small Moderate Big
problem problem problem problem problem
a. Hot flashes  ⁮ ⁮ ⁮ ⁮ ⁮
b.
b. Breast tenderness/
enlargement.. ⁮ ⁮ ⁮ ⁮ ⁮
c. Loss of body hair.. ⁮ ⁮ ⁮ ⁮ ⁮
d. Feeling depressed. ⁮ ⁮ ⁮ ⁮ ⁮
e. Lack of energy. ⁮ ⁮ ⁮ ⁮ ⁮
f. Change in body weight ⁮ ⁮ ⁮ ⁮ ⁮
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